

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Descriptive analysis of Spanish national trends of coronary artery bypass grafting and percutaneous coronary intervention from 1998 to 2017.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-046141
Article Type:	Original research
Date Submitted by the Author:	21-Oct-2020
Complete List of Authors:	CARNERO ALCAZAR, MANUEL; Hospital Clínico Universitario San Carlos Instituto Cardiovascular, Cardiac Surgery Hernandez-Vaquero, Daniel ; Hospital Universitario Central de Asturias, Cardiac Surgery Lopez Menendez, Jose; Hospital Ramon y Cajal, Cardiac Surgery Piñon, Miguel; Alvaro Cunqueiro Hospital, Cardiac Surgery Albors Martin, Jose; Hospital Universitario del Vinalopó, Cardiac Surgery Cuerpo Caballero, Gregorio; Hospital General Universitario Gregorio Marañón, Cardiac Surgery Cobiella Carnicer, Javier; Hospital Clínico Universitario San Carlos Instituto Cardiovascular, Cardiac Surgery Villamor, Cristina; Hospital Clinico Universitario San Carlos, Internal Medicine Forteza, Alberto; Puerta del Hierro University Hospital of Majadahonda, Cardiac Surgery Maroto Castellanos, Luis; Hospital Clínico Universitario San Carlos Instituto Cardiovascular, Cardiac Surgery
Keywords:	Coronary heart disease < CARDIOLOGY, Cardiac Epidemiology < CARDIOLOGY, PUBLIC HEALTH, Cardiac surgery < SURGERY, Coronary intervention < CARDIOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Title: Descriptive analysis of Spanish national trends of coronary artery bypass grafting**
4 **and percutaneous coronary intervention from 1998 to 2017.**
5

6 **Authors:**
7

8 Manuel Carnero-Alcázar(1), Daniel Hernandez-Vaquero(2), José López-Menéndez(3),
9 Miguel Piñón(4), José Albors-Martín(5), Gregorio Cuerpo-Caballero(6), Javier Cobiella-
10 Carnicer(1), Cristina Villamor (1), Alberto Forteza (7), Luis C Maroto-Castellanos(1)
11

- 12 1.Hospital Clínico San Carlos. Madrid. Spain.
13 2.Hospital Central de Asturias. Oviedo. Spain.
14 3.Hospital Ramón y Cajal. Madrid. Spain.
15 4.Hospital Álvaro Cunqueiro. Vigo. Spain.
16 5.Hospital del Vinalopó. Alicante. Spain.
17 6.Hospital Gregorio Marañón. Madrid. Spain.
18 7.Hospital Puerta de Hierro. Majadahonda. Spain.
19
20
21

22 **Corresponding author:** Manuel Carnero Alcázar. Dpt. of Cardiac Surgery. Hospital Clínico
23 San Carlos. Plaza Cristo Rey s/n.28040. Madrid. Spain. Email:
24 manuel.carnero@salud.madrid.org Tlph: +34646773287
25

26 **Word Count: 5025**

27 **Structured abstract & article summary: 354**

28 **Abstract: 268**

29 **Text: 2848**

30 **References: 887**

31 **Tables and Figures: 976**
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Article Summary

Abstract

Introduction. Spain is one of the countries with the lowest rates of revascularization and highest percutaneous coronary intervention (PCI) to coronary artery bypass grafting (CABG) rates.

Objectives. To investigate the changes and trends in the two revascularization procedures between 1998 and 2017 in our country.

Design. Retrospective cohort study. Analysis of in-hospital outcomes.

Setting. Large mandatory database from the Spanish National Department of Health collecting information of patients who are attended in Spanish public National Health System.

Participants. 596,810 patients who underwent isolated CABG or PCI in the Spanish National Health System. The study period was divided in 4 5-year intervals. Patients with acute myocardial infarction were excluded.

Primary and Secondary Outcomes: We investigated the volume of procedures nationwide, the changes in the risk profile of patients and in-hospital mortality of both techniques.

Results. We observed a 3-fold increase in the number of patients undergoing any type of myocardial revascularization: 14241(1998) to 39759(2017). 93,677 (15.7%) had a coronary surgery. PCI to CABG ratio rose from 2.2 (1998-2002) to 7.7 (2013-2017). Charlson's index increased by 0.8 for CABG and 1 for PCI. The median annual volume of PCI/hospital augmented from 136 to 209, while the volume of CABG was reduced from 137 to 72. In the two decades, we detected a significant reduction of CABG in-hospital mortality (6.5% Vs 2.6%, $p<0.001$) and a small increase in PCI (1.2% Vs 1.6%, $p<0.001$). Risk adjusted mortality rate was reduced for both CABG (1.55 Vs 0.44, $p<0.001$), and PCI (1.72 Vs. 0.85, $p<0.001$).

Conclusion. We detected a significant increase in the volume of revascularizations (particularly PCI) in Spain. Risk-adjusted in-hospital mortality has been significantly reduced

Strengths and limitations.

- This is the first study to investigate the nationwide changes and trends in coronary revascularization in Spain during the past two decades.
- It was based on a very large and detailed administrative database which included most of the episodes of patients who have been admitted to any public NHS hospital between 1998-2017.
- Follow up information is not available
- The analysis might be biased by administrative information coding errors.
- However, no other source of information allows to perform a long-term nationwide investigation like this.

INTRODUCTION

Surgical and percutaneous myocardial revascularization have demonstrated to improve symptoms and life expectancy in patients with advanced coronary artery disease. In the vast majority of patients with ST-elevation acute coronary syndrome, percutaneous coronary intervention (PCI) is the preferred strategy(1). However, in chronic stable angina or non-ST elevation acute coronary syndrome, the choice between PCI and coronary surgery bypass grafting (CABG) depends on multiple factors. In this scenario, the best therapeutic option for each patient must be decided(1,2) by a multidisciplinary “Heart Team”.

Many authors have investigated large national registries and analyzed the changes of both techniques over time and the distribution of CABG and PCI across different regions and countries (3-6). Spain is, according to the OECD(6), one of the European countries with the lowest revascularization rates and the one with the highest ratio of PCI to CABG among patients with coronary artery disease. The causes of the magnitude of this disbalance have never been studied in depth. Moreover, there is no robust evidence on the evolution of the two techniques in terms of their results and variability, and the risk profile of CABG and PCI patients in the Spanish National Health System (NHS).

In our country, there are no patient-level clinical registries specifically dedicated to patients with coronary artery disease undergoing myocardial revascularization. The Spanish Society of Thoracic and Cardiovascular Surgery and the Spanish Society of Cardiology annually report the volume and outcomes of CABG and PCI in Spain(7,8). However, these reports are based on voluntary, aggregated and unaudited information submitted by hospitals. On the other hand, the healthcare centers of the Spanish NHS have to report the administrative information of all admitted patients to a mandatory nationwide registry: The Minimum Basic Dataset (MBDS) from the Department of Health. The MBDS stores individual and anonymized data from all discharge reports from all the NHS episodes, coded according to the International Classification of Diseases (ICD) in its 9th and 10th edition. Despite the fact that the use of non-specific administrative sources, such as this one, for the analysis of clinical indicators in the field of cardiology is controversial(9), different studies based on the MBDS have validated its usefulness to analyze the results of clinical processes in Spain(10-14)

We set out to study the evolution of CABG and PCI in Spain between 1998 and 2017 with the information obtained from the MBDS of the Department of Health of our country. Specifically, we analyzed the volume of CABG and PCI, the changes in the risk profile of patients and hospital mortality in the two revascularization strategies. It was not the objective of this study to compare the results of both techniques, taking into account that they have different indications and that follow-up information is not available.

MATERIALS AND METHODS

Sources of information and patient selection

Data was obtained from the MBDS from the Department of Health of Spain. This research was carried out according to the STROBE (Strengthening the Reporting of OBservational studies in Epidemiology) recommendations. This study was approved by the Institutional Review Board and Ethics Committee at Hospital Clínico San Carlos (Madrid,Spain).

The patient selection algorithm can be seen in Figure 1. We investigated all the outpatient or hospitalization episodes of the Spanish NHS from 1998 to 2017 in which a CABG or PCI procedure had been carried out. Those patients undergoing concomitant procedures were excluded (See supplemental Table 1 ICD9 and ICD10 codes).

Likewise, all episodes with an acute myocardial infarction/acute coronary syndrome with ST segment elevation as the primary diagnosis (See supplemental Table 1) were excluded, as those who received both types of revascularization in the same episode. In addition, to avoid possible coding errors, patients younger than 18 or older than 100-year-old, patients operated on CABG in centers without CABG or who underwent PCI in centers without PCI were also discarded. Patients discharged alive earlier than two days after the procedure were also considered as coding

1
2
3 errors. The episodes corresponding to patients who were transferred to another center and
4 consecutive planned revascularization episodes were consolidated into a single episode(14). The
5 full period of time (1998-2017) was divided in four 5-year intervals (1998-2002, 2003-2007, 2008-
6 2012 and 2013-2017).
7

8 *Patient and Public Involvement*

9

10 No patient was actively involved in the study. Information regarding the delivered healthcare to
11 the patients included in this investigation was obtained deidentified from the Spanish Department
12 of Health
13

14 *National volume of revascularization procedures and risk profile of the patients*

15

16 We investigated the absolute number of CABG and PCI per year, the number of
17 procedures per million of inhabitants and the changes in the PCI/CABG ratio. To estimate the
18 nationwide population, data was extracted from the National Institute of Statistics(15).
19

20 Healthcare centers were classified according to the volume of procedures per year. Thus,
21 for both CABG and PCI, hospitals were divided into four groups according to the quartile of the
22 volume of PCI or CABG interventions that they performed in each year: Low volume (quartile
23 1), Low-Intermediate Volume (quartile 2), High-Intermediate Volume (quartile 3) and High
24 Volume (quartile 4) .
25

26 Patients were classified into four groups according to their age (≤ 60 , >60 & ≤ 70 , >70 & ≤ 80 ,
27 and >80 -year-old). We analyzed the evolution of the prevalence of various comorbidities (see
28 Table 1). Age-modified Charlson's Index was calculated (16,17). In addition, the individual
29 components of this score (myocardial infarction, kidney disease, diabetes, ...) and other
30 procedural variables were analyzed throughout the study period.
31

32 *Mortality*

33

34 We analyzed in hospital non-adjusted and adjusted mortality for PCI and CABG and its
35 changes over the study period.
36

37 *Statistical Analysis.*

38

39 Categorical variables were represented with absolute and relative frequencies (%) and were
40 compared with the chi-squared test. The normality of the quantitative variables was analyzed with
41 PP- plots, and they were expressed with mean and standard deviation or median and interquartile
42 range. Quantitative variables were compared among the periods of the study with an analysis of
43 variance or non-parametric comparison of medians. Contrasts were performed to investigate the
44 presence of a linear trends (LT). The relative risk reduction (RRR) and odds ratio (OR) were used
45 to represent the strength of association between different variables and mortality.
46

47 We investigated factors associated to mortality for each type of revascularization. For this
48 purpose, we created multivariate models including variables with theoretical value and variables
49 related to mortality (statistical significance $p < 0.1$) in an univariate analysis. The best models were
50 selected based on the value of the Akaike information criterion, R^2 and their area under the curve.
51 Using the mortality risk estimated by these models, we calculated the risk- adjusted mortality rate
52 (RAMR) by dividing the observed and expected mortality (14).
53

54 Statistical analysis was performed with Stata v 15.0 (StataCorp. 2017. Stata Statistical
55 Software:Release 15.College Station,TX: StataCorp LLC.)
56

56 **RESULTS**

57

58 *Study Population*

59
60

1
2
3 Almost one million (977,797) patients underwent CABG or PCI in the study period.
4 Thirty nine percent (381,167) were excluded and 596,810 patients were considered for the
5 purpose of this study. Of these, 93,677(15.7%) had CABG and 503,133(84.3%) PCI. There was a
6 linear increase ($p_{TL}<0.001$) in the PCI/CABG ratio: 1998-2002: 2.2(69% PCI vs. 31% CABG), 2003-
7 2007:5(83.3% PCI Vs. 16.7% CABG), 2008-2012:7.6 (88.3% PCI Vs. 11.7% CABG), and 2013-
8 2017:7.7(88.5% PCI Vs. 11.5% CABG) (Table 1). In the global series, an increase in the number of
9 revascularizations was observed with an increase in the number of PCI and a reduction in the
10 number of CABG (Figure 2). Given the national population in Spain, in 1998, 357
11 revascularizations per million inhabitants were carried out, while in 2017 it was 855. In the same
12 interval, the number of CABG per million decreased from 138 to 102, and the number of PCI
13 increased from 219 to 752 per million inhabitants (Figure 2).

14 The risk profile of patients worsened throughout the study period (table 1). In PCI and
15 CABG groups, we observed an increase in the mean age and in the prevalence of risk factors such
16 as previous myocardial infarction, heart failure, peripheral vascular disease, diabetes or COPD.
17 Consequently, Charlson's Index rose up from 2.7 to 3.5($p_{TL}<0.001$) among CABG patients and
18 from 2.6 to 3.6 ($p_{TL}<0.001$) in PCI .

19 The proportion of patients who were revascularized electively decreased in the two
20 groups($p_{TL}<0.001$). We detected an increase in PCI activity in centers without CABG: in 1998-
21 2002, only 17.4% of patients underwent PCI in a center without CABG, while between 2013 and
22 2017, the proportion increased to 41.1%($p_{TL}<0.001$).

23 The proportion of patients who had three or more coronary arteries revascularized was
24 higher in the CABG group (40.5% Vs 8.4%, $p<0.001$). We observed a linear increase in the use
25 of bilateral internal thoracic arteries (8% Vs. 23.6 %, $p_{TL}<0.001$), and off-pump CABG (31.3%
26 Vs. 34.2% $p_{TL}<0.001$) from the first to the last period.

27 *Mortality*

28 Among patients undergoing CABG, a decrease in non-adjusted in-hospital mortality
29 was observed between 1998 and 2017: 6.5% Vs. 2.6% ($p_{TL}<0.001$; RRR -0.6, 95%CI -0.67;-0.53).
30 Mortality among patients undergoing PCI increased slightly from 1.2% to 1.6% ($p_{TL}<0.001$; RRR
31 +1.33, 95%CI 0.31;0.35)(Figure 3A).

32 Table 2 shows factors independently associated to in-hospital mortality after CABG or PCI. Most of
33 the factors increased mortality regardless of the type of revascularization (COPD, age, previous
34 infarction, heart failure, etc...). The effect of some variables changed depending on the type of
35 revascularization such as the hospital volume of procedures. PCI mortality in centers without
36 CABG was lower than in centers with CABG on site (OR 0.87,95%CI 0.81; 0.93, $p<0.001$).
37 Mortality was independently reduced by the study period.

38 Information regarding the estimation of RAMR is shown in Table 2 in the
39 supplementary material. A decrease in RAMR was detected in both CABG and PCI patients. In
40 the case of coronary surgery, the RAMR decreased from 1.55 to 0.44($p_{TL}<0.001$), and in the case of
41 PCI from 1.72 to 0.85($p_{TL}<0.001$) between 1998 and 2017 respectively (see Figure 3B).

42 *Volume of activity and mortality by center*

43 The number of centers with CABG and PCI on site increased from 37 (1998-2002) to 48
44 (2013-2017)($p_{TL}<0.001$)(table 3 and supplementary Figure 1). The number of centers with PCI but
45 without CABG on site increased from 25 (1998) to 96 (2017) (see Table 3). We observed an
46 increase in the median volume of PCI per center from 136 to 209($p_{TL}<0.001$) and a decrease in
47 CABG from 137 to 72 CABG($p_{TL}<0.001$) between 1998 and 2017. (Supplementary figure 1). The
48 volume of interventions was independently associated to a lower in-hospital mortality for CABG and
49 a higher mortality after PCI (see table 3)

50 **DISCUSSION**

1
2
3 Between 1998 and 2017, in Spain, the volume of revascularizations/million inhabitants
4 in patients with stable angina or acute coronary syndromes without ST elevation increased to 852
5 (See Figure 2). However, these rates are very low as compared to other countries. For example,
6 in the United States, the number of CABG per million inhabitants in 2007-2008 was 1,081/year,
7 while that of PCI was 3,667/year(18). In Germany, in 2013, the proportion of revascularizations
8 per 100,000 inhabitants was three times higher than in Spain(6). Although the differences can be
9 explained by the lower prevalence of coronary heart disease in our country, there are other factors
10 that may influence such as a greater difficulty in accessing the healthcare system for patients or a
11 less frequent indication for revascularization.

12 In addition, there was, over the past 20 years, a 13.5% reduction in the volume of CABG
13 (5509 in 1998 Vs 4756 in 2017) and a 178.7% increase of PCI volume (14245 in 1998 Vs 39636
14 in 2017). The PCI/CABG ratio in the last period of the study was 7.7. In the 2015 “*Health at a
15 Glance*” report, the PCI/CABG ratio was 7.3 in Spain, very similar to that observed in this study
16 and more than double the average of the countries included in that report: 3.55(6). Similar changes
17 have happened in other countries. For example, the analysis of the US National Inpatient Sample
18 registry found a reduction in CABG volume of 116% between 1998 and 2015(19) and 14%
19 between 2001 and 2007 with a stabilization of the volume of PCI procedures(18). The New York
20 State registry detected an increase in the PCI/CABG ratio between 1994 and 2008 from 1.12 to
21 5.14(5). The ratio observed in the present study, however, is difficult to compare since we have
22 excluded revascularizations among patients with acute myocardial infarction which were
23 considered in other reports (6). Therefore, the PCI to CABG ratio in Spain might be even higher.

24 A significant worsening of the risk profile has been observed for both PCI and CABG
25 patients: 14% increase in the prevalence of diabetes, proportion of patients with severe chronic kidney
26 disease has multiplied by 6 and that of COPD by 2 (see Table 1)... In general, the increased risk of
27 patients is consistent with a progressive aging of patients and an increase in the prevalence and
28 severity of cardiovascular risk factors observed in Spain and other countries(20- 22). Despite the
29 conflicting evidence on the benefit of off pump CABG or multiple arterial grafts revascularization,
30 in Spain there has been an increase in the number of patients operated on with two or more internal
31 thoracic arterial grafts (8% in the first period Vs. 23.6 % between 2013 and 2017($p_{TL}<0.001$)) or off
32 pump (31.3% Vs 34.2% in the first and last period respectively, $p_{TL}<0.001$)(23,24).

33 Mortality after CABG in Spain has decreased from 6.5% in 1998 to 2.6% in 2017 and is now
34 similar to that of other countries (21). The strong reduction of mortality is a common finding too: for
35 example, the registry for New South Wales detected a decrease in hospital mortality after CABG
36 of 30% between 2000 and 2013(26). Beyond the reduction in non-adjusted mortality, a significant
37 reduction in risk-adjusted mortality was observed too. Between 1998 and 2017, the risk-adjusted
38 death rate decreased in CABG almost 4 times (1.55 to 0.44($p_{TL}<0.001$)).

39
40
41 Hospital mortality after PCI in Spain was similar to that of other developed countries(26,27), and
42 slightly increase throughout the series. However, when adjusting for patient comorbidities and
43 other confounding factors, the RAMR was reduced by almost half (1.72 to 0.85($p_{TL}<0.001$)). In
44 Spain, we have detected a fourfold increase in the number of centers that perform PCI without CABG
45 (see Table 3). Between 2013 and 2017, 41.1% of the patients treated with PCI were revascularized
46 in a center without coronary surgery. On addition, there has been a very significant decrease in the
47 median number of CABG procedures per center between the first and last period of the study (130.5
48 Vs 74.5, $p_{TL}<0.001$). This volume of interventions per center is different from that reported by
49 Goicolea et al.(15) who detected a mean number of CABG procedures of 95/year between 2013
50 and 2015. Goicolea et al. misclassified procedures such as combined surgery of the aorta,
51 pericardium, ventricular remodeling or cardiac arrhythmias as isolated coronary surgery
52 interventions, which can explain the differences. In any case, the volume of CABG or PCI per center
53 in Spain is very low. For example, in Europe, hospitals with an intermediate volume of CABG
54 perform between 125 and 450 procedures per year(28) and the EACTS/ESC Myocardial
55 Revascularization Guidelines recommend a minimum of 200 isolated CABG interventions to
56 maintain viable coronary surgery programs(1).

57 There is an important relationship between the volume of CABG per center and in-
58 hospital mortality, such that as the volume of the centers increases, mortality decreases. (Table 2 and
59
60

1
2
3 3). On the contrary, mortality after PCI increases as the volume of interventions increases (Table 2
4 and 3). The latter can be explained by the fact that patients referred to centers with greater activity
5 may have anatomical characteristics or comorbidities that confer a greater risk, and which have
6 not been contemplated in this study.

7 *Conclusions*

8
9 In the last 20 years there has been a significant increase in the volume of revascularizations in
10 Spain. This increase has been uneven, with a significant increase in PCI and a gradual reduction in
11 CABG. Risk-adjusted mortality has been significantly reduced in both arms, although the
12 intensity of the reduction has been particularly intense among surgically revascularized patients.
13 Finally, there is a significant atomization of revascularization in Spain, with centers with a low
14 volume of CABG and a large number of hospitals that have PCI programs in their service portfolio
15 but not CABG.

16 17 18 *Limitations*

19
20 These conclusions have to be taken with caution due to possible coding biases and others inherent
21 to administrative databases analyses. We could not estimate operative risk according to validated
22 scales in cardiac surgery (such as EuroSCORE). The MBDS does not contain information on private
23 activity in Spain, which account for 10% of healthcare delivery in Spain.

24 25 26 27 **Footnotes:**

28 **Author Contributions:** MCA, DHV, LCMC and JLM contributed to developing the design of
29 the study. MCA and LCMC requested the information from the Spanish Department of Health.
30 MCA, MP, JAM, CV and GCC contributed to interpreting the data. MCA, JCC, DVH performed
31 the statistical analysis. AF and LCMC contributed to the critical review of the paper. MCA is the
32 guarantor of this work and assumes full responsibility for the conduct of the study

33 **Funding Statement:**

34 This research received no grant from any funding agency in the public, commercial or not-for-
35 profit sectors

36 **Competing interests:** None.

37 Patient consent for publication: Not required

38 **Ethics approval:** This study was approved by the Institutional Review Board and Ethics
39 Committee at Hospital Clínico San Carlos (Madrid)

40 **Data availability statement:** Data was provided deidentified by the *Unit of Health Care*
41 *Information and Statistics* (Spanish Department of Health), which stores securely the information
42 in their remote servers. This information is public and was provided only for investigation
43 purposes.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References:

1. Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. *Eur Heart J*.2019;40:87-165.
2. Mohr FW, Morice MC, Kappetein AP, Feldman TE, Ståhle E, Colombo A, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomized, clinical SYNTAX trial. *Lancet*.2013;381:629–38.
3. Blumenfeld O, Na'amnih W, Shapira-Daniels A, Lotan C, Shohat T, Shapira OM. Trends in Coronary Revascularization and Ischemic Heart Disease-Related Mortality in Israel. *J Am Heart Assoc*.2017;6:e004734.
4. Epstein AJ, Polsky D, Yang F, Yang L, Groeneveld PW. Coronary revascularization trends in the United States, 2001-2008. *JAMA*.2011;305:1769-76.
5. Ko W, Tranbaugh R, Marmur JD, Supino PG, Borer JS. Myocardial Revascularization in New York State: Variations in the PCI-to-CABG Ratio and Their Implications. *J Am Heart Assoc*.2012;1:e001446.
6. Health at a Glance: Europe 2016. State Of Health In The Eu Cycle. Available at: https://ec.europa.eu/health/sites/health/files/state/docs/health_glance_2016_rep_en.pdf. Accessed April 28,2020.
7. Cuerpo G, Carnero M, Hornero Sos F, Polo ML, Centella Hernandez T, Gascón P, et al. Cirugía cardiovascular en España en el año 2018. Registro de intervenciones de la Sociedad Española de Cirugía orácica-Cardiovascular. *Cir Cardiovasc*.2019;26:248-64.
8. Cid Álvarez AB, Rodríguez Leor O, Moreno R, Pérez de Prado A. Registro Español de Hemodinámica y Cardiología Intervencionista. XXVII Informe Oficial de la Sección de Hemodinámica y Cardiología Intervencionista de la Sociedad Española de Cardiología (1990-2017). *Rev Esp Cardiol*.2018;71:1036-46.9. Mack MJ, Herbert M, Prince S, Dewey TM, Magee MJ, Edgerton JR. Does reporting of coronary artery bypass grafting from administrative databases accurately reflect actual clinical outcomes?. *J Thorac Cardiovasc Surg*.2005;129:1309–17.
10. Íñiguez Romo A, Bertomeu Martínez V, Rodríguez Padial L, Anguita Sanchez M, Ruiz Mateas F, Hidalgo Urbano R, et al. The RECALCAR Project. Healthcare in the Cardiology Units of the Spanish National Health System, 2011 to 2014. *Rev Esp Cardiol (Engl Ed)*.2017;70:567-575.
11. Rodríguez-Padial L, Bertomeu V, Elola FJ, Anguita M, Fernandez Lozano I, Sila L, et al. Quality improvement Strategy of the Spanish Society of Cardiology: The RECALCAR Registry. *J Am Coll Cardiol*.2016;68:1140-2.
12. Bertomeu V, Cequier Á, Bernal JL, Alfonso F, Anguita M, Barrabés JA, et al. In-hospital mortality due to acute myocardial infarction. relevance of type of hospital and care provided. RECALCAR study. *Rev Esp Cardiol(Engl Ed)*.2013; 66:935-42.
13. Gutacker N, Bloor K, Cookson R, Garcia-Armesto S, Bernal-Delgado E. Comparing hospital performance within and across countries: an illustrative study of coronary artery bypass graft surgery in England and Spain. *Eur J Public Health*.2015;25 Suppl 1:28–34.
14. Goicolea Ruigómez FJ, Elola FJ, Durante-López A, Fernández Pérez C, Bernal JL, Macaya C. Coronary artery bypass grafting in Spain. Influence of procedural volume on outcomes. *Rev Esp Cardiol (Engl Ed)*.2020[Epub ahead of print].
15. INEbase [Internet]. Madrid: Instituto Nacional de Estadística (Spain); [cited 2019, July, 20]. Available from: <http://www.ine.es/>.
16. Charlson ME, Szatrowski TP, Peterson J, Gold J. Validation of combined comorbidity index. *J Clinical Epidemiol*.1994;47:1245-51.
17. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, et al. Validation of the combined comorbidity index of Charlson and Elixhauser to predict 30-day mortality across ICD 9 and ICD 10. *Med Care*.2018;56:812.
18. Epstein AJ, Polsky D, Yang F, Yang L, Groeneveld PW. Coronary Revascularization trends in the United States:2001-2008. *JAMA*.2011;305:1769–1776.

19. Becker ER, Granzotti AM. Trends in In-hospital Coronary Artery Bypass Surgery Mortality by Gender and Race/ Ethnicity –1998-2015: Why Do the Differences Remain?. *J Natl Med Assoc.*2019;111:527-539.
20. Cornwell LD, Omer S, Rosengart T, Holman WL, Bakaeen FG. Changes over time in risk profiles of patients who undergo coronary artery bypass graft surgery: the Veterans Affairs Surgical Quality Improvement Program (VASQIP). *JAMA Surg.*2015;150:308-15
21. Beckmann A, Meyer R, Lewandowski J, Markewitz A, Harringer W. German Heart Surgery Report 2018: The Annual Updated Registry of the German Society for Thoracic and Cardiovascular Surgery. *Thorac Cardiovasc Surg.*2019;67:331-344.
22. Vora AN, Dai D, Gurm H, Amin AP, Messenger JC, Mahmud E, et al. Temporal Trends in the Risk Profile of Patients Undergoing Outpatient Percutaneous Coronary Intervention: A Report from the National Cardiovascular Data Registry's CathPCI Registry. *Circ Cardiovasc Interv.*2016;9:e003070.
23. Taggart DP, Altman DG, Gray AM, Lees B, Nugara F, Yu LM, et al. Randomized trial to compare bilateral vs. single internal mammary coronary artery bypass grafting: 1-year results of the Arterial Revascularisation Trial (ART). *Eur Heart J.*2010;31:2470-81.
24. Shroyer AL, Hattler B, Wagner TH, Collins JF, Baltz JH, Quin JA, et al. Five-Year Outcomes after On-Pump and Off-Pump Coronary-Artery Bypass. *N Engl J Med.*2017;377:623-632.
25. Brieger DB, Ng ACC, Chow V, D'Souza M, HyunK, Bannon PG, et al. Falling hospital and postdischarge mortality following CABG in New South Wales from 2000 to 2013. *Open Heart.*2019;6:e000959.
26. Tran DT, Barake W, Galbraith D, Norris C, Knudtson ML, Kaul Pet al. Total and Cause-Specific Mortality After Percutaneous Coronary Intervention: Observations From the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease Registry. *CJC Open.* 2019 Jun 8;1:182-189.
27. Spoon DB, Psaltis PJ, Singh M, Holmes DR Jr, Gersh BJ, Rihal CS, et al. Trends in cause of death after percutaneous coronary intervention. *Circulation.*2014;129:1286-94.
28. Gutacker N, Bloor K, Cookson R, Gale CP, Maynard A, Pagano D, et al. Hospital Surgical Volumes and Mortality after Coronary Artery Bypass Grafting: Using International Comparisons to Determine a Safe Threshold. *Health Serv Res.*2017;52:863-878.

	CABG					PCI					GLOBAL		
	1998-2002	2003-2007	2008-2012	2013-2017	p _(TL)	1998-2002	2003-2007	2008-2012	2013-2017	p _(TL)	CABG	PCI	p
n(%) ^a	27146(31)	24522(16.7)	21594(11.7)	20415(11.5)	<0.001	60451(69)	122350(83.3)	163342(88.3)	156990(88.5)	<0.001	93677(15.7)	503133(84.3)	<0.001
Age(years)	64.9±9.5	66±9.7	66.1±10	66.3±9.7	<0.001	64±11	65.9±11.1	67±11.5	67.6±11.6	<0.001	65.8±9.7	66.6±11.5	<0.001
Age(ranges)					<0.001*					<0.001*			
≤60	7635(28.1)	6498(26.5)	5797(26.9)	5354(26.2)	<0.001	20890(34.6)	36811(30.1)	45328(27.8)	42679(27.2)	<0.001	25284(27)	145708(29)	<0.001
60-70	10295(37.9)	8073(32.9)	7212(33.4)	7222(35.4)	<0.001	19448(32.2)	34787(28.4)	45310(27.7)	43708(27.8)	<0.001	32802(35)	143253(28.5)	<0.001
70-80	8685(32)	9078(37)	7437(34.4)	6573(32.2)	<0.001	17402(28.8)	40412(33)	51540(31.6)	45195(28.8)	<0.001	31773(33.9)	154549(30.7)	<0.001
>80	531(2)	873(3.6)	1148(5.3)	1266(6.2)	<0.001	2711(4.5)	10340(8.5)	21164(13)	25408(16.2)	<0.001	3818(4.1)	59623(11.9)	<0.001
Female sex	5380(19.8)	4768(19.5)	3778(17.5)	3345(16.4)	<0.001	13192(21.8)	29707(24.3)	39883(24.4)	37652(24)	<0.001	17271(18.4)	120434(23.9)	<0.001
High blood pressure	12266(45.2)	14540(59.3)	14169(65.6)	13800(67.6)	<0.001	26009(43)	68911(56.3)	100988(61.8)	98855(63.1)	<0.001	54775(58.5)	294763(58.6)	0.057
Previous MI ^b	3472(12.8)	3944(16.1)	3330(15.4)	4119(20.2)	<0.001	11383(18.8)	29619(24.2)	46776(28.6)	54703(34.8)	<0.001	14865(15.9)	142481(28.3)	<0.001
NSTEACS	8291(30.2)	6085(24.8)	4541(21)	4228(20.7)	<0.001	25498(42.2)	44829(36.6)	53406(32.7)	49946(31.8)	<0.001	23045(24.6)	173679(34.5)	<0.001
CHF ^b	1599(5.5)	1737(7.1)	2102(9.7)	2104(10.3)	<0.001	2745(4.5)	9474(7.7)	17725(10.9)	20199(12.9)	<0.001	7442(7.9)	50143(10)	<0.001
PVD ^b	1751(6.5)	2240(9.1)	2239(10.4)	2181(10.7)	<0.001	4430(7.3)	10382(8.5)	12585(7.7)	11587(7.4)	<0.001	8411(9)	38984(7.8)	<0.001
CVD ^b	746(2.8)	1122(4.6)	1223(5.7)	1360(6.7)	<0.001	897(1.5)	2566(2.1)	4420(2.7)	4619(2.9)	<0.001	4451(4.8)	124502(2.5)	<0.001
Diabetes ^b	7494(27.6)	8799(35.9)	8510(39.4)	8797(43.1)	<0.001	13131(21.7)	3783(31)	55318(33.9)	54629(34.8)	<0.001	33600(35.9)	1609719(32)	<0.001
CKD ^b	423(1.6)	701(2.9)	1442(6.7)	1946(9.5)	<0.001	1066(1.8)	3688(3)	12219(7.5)	15107(9.6)	<0.001	4512(4.8)	32080(6.4)	<0.001
COPD ^b	961(3.5)	1396(5.7)	1322(6.1)	1518(7.4)	<0.001	2241(3.7)	6279(5.1)	10273(6.3)	11717(7.5)	<0.001	5196(5.6)	30510(6.1)	<0.001
Liver failure ^b	241(0.9)	331(1.4)	410(1.9)	560(2.7)	<0.001	460(0.8)	1392(1.1)	2499(1.5)	3455(2.2)	<0.001	1542(1.7)	7806(1.6)	0.101
Charlson's Index	2.7(1.4)	3.1(1.5)	3.3(1.7)	3.5(1.8)	<0.001	2.6(1.5)	3(1.7)	3.4(1.9)	3.6(2)	<0.001	3.1(1.6)	3.3(1.9)	<0.001
Previous CABG	1088(4)	1070(4.4)	130(0.6)	132(0.7)	<0.001	1691(2.8)	3255(2.7)	4128(2.5)	4686(3)	<0.001	2421(2.6)	13760(2.7)	0.007
Previous PCI	1517(5.6)	1895(7.7)	2555(11.8)	3014(14.8)	<0.001	7835(13)	21700(17.7)	38928(23.8)	43158(27.5)	<0.001	8981(9.6)	111621(22.2)	<0.001
Non-elective Procedure	10474(38.6)	8951(36.7)	7990(37.2)	5014(40.1)	<0.001	32980(54.8)	75290(62.1)	102762(64.1)	66459(66.7)	<0.001	32428(37.9)	277491(66.7)	<0.001
Hospital without CABG on site	-	-	-	-	-	10151(17.4)	36428(30.7)	65011(40.9)	62398(41.1)	<0.001	-	173988(35.7)	-
Revascularization +3 vessels	9321 (40.3)	8558(40.7)	7514(40.3)	7456(40.6)	0.071	-	-	12322(8.5)	12333(8.4)	<0.001	32849(40.5)	24655/292945 (8.4)	0.053
ITA	19643(72.3)	21635(88.2)	19646(90.9)	19928(96.9)	<0.001	-	-	-	-	-	80852(86.1)	-	-
Bilateral ITA	2168(8)	3218(13.1)	3457(16)	4814(23.6)	<0.001	-	-	-	-	-	13657(14.6)	-	-
Off Pump CABG	8497(31.3)	8709(35.5)	7182(33.3)	6977(34.2)	<0.001	-	-	-	-	-	31365(33.5)	-	-
Hospital Volume					<0.001*					<0.001*			<0.001
Low	3971(15.1)	3053(12.6)	2406(11.2)	2077(10.7)	<0.001	3260(5.6)	6006(5.1)	7575(4.8)	7628(5)	<0.001	11407(12.6)	24459(5)	<0.001
Low- Intermediate	5511(21.5)	4671(19.3)	4276(19.9)	3680(18.9)	<0.001	8159(14)	17227(14.5)	21343(13.4)	21522(14.2)	<0.001	18138(20)	68351(14)	<0.001
Intermediate-High	7149(27.8)	6984(28.8)	6449(30)	5495(28.2)	<0.001	15955(27.4)	33550(28.3)	45385(28.6)	45144(29.7)	<0.001	26077(28.7)	140034(28.7)	0.128
High	9157(35.7)	9525(39.3)	8377(39)	8232(42.3)	<0.001	30872(53)	61926(52.2)	84660(53.3)	77549(51)	<0.001	35291(38.8)	255007(52.3)	<0.001

1 Table 1. Baseline and procedural characteristics of PCI (percutaneous coronary intervention) or CABG (Coronary artery bypass grafting). Data is expressed
2 with n(%) or mean SD. $p_{(TL)}$ contrast test for linear trend. *No contrast for linear trend. a. Number of CABG or PCI divided by the volume of revascularizations.
3 b. according to Charlson's index definition(17,18). MI: Myocardial infarction. CHF: Congestive heart failure. PVD: peripheral vascular disease. CKD: Chronic
4 kidney disease. CVD: Cerebrovascular disease. COPD Chronic obstructive pulmonary disease: ITA: internal thoracic artery.
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

CABG			PCI		
Variable	OR CI 95%	p	Variable	OR CI 95%	p
Region of Spain	Not Shown	<0.001	Region of Spain	Not Shown	<0.001
Hospital Volume of CABG (as compared to Low Volume centers)			Hospital Volume of PCI (as compared to Low Volume centers)		
Low-Intermediate	0.87(0.77;0.96)	0.001	Low-Intermediate	1.36(1.14;1.63)	<0.001
Intermediate-High	0.8(0.72;0.89)	<0.001	Intermediate-High	2(1.68; 2.37)	<0.001
High	0.76(0.68;0.85)	<0.001	High	1.94 (1.62;2.31)	<0.001
COPD	1.36(1.2;1.54)	<0.001	COPD	1.29(1.18;1.39)	<0.001
Age (as compared to <60)			Age (as compared to <60)		
60-70	1.74(1.57;1.93)	<0.001	60-70	1.67(1.52;1.84)	<0.001
70-80	3.08(2.79;3.39)	<0.001	70-80	2.63(2.41;2.87)	<0.001
>80	5.23(4.51;6.05)	<0.001	>80	3.85(3.5;4.23)	<0.001
Female sex	1.14(1.06;1.23)	0.001	Female sex	1.08(1.02;1.15)	0.016
Previous MI	2.81(2.62;3.01)	<0.001	Previous MI	2.63(2.5;2.77)	<0.001
NSTE ACS as primary diagnosis	1.19(1.11;1.28)	<0.001	NSTE ACS as primary diagnosis	0.96(0.9;1.02)	0.151
CHF	3.21(2.96;3.49)	<0.001	CHF	4.68(4.43;4.94)	<0.001
PVD	1.43(1.3;1.59)	<0.001	PVD	1.24(1.15;1.34)	0.002
CVD	1.74(1.54;1.96)	<0.001	CVD	2.33(2.11;2.57)	<0.001
CKD	1.77(1.56;2.01)	<0.001	CKD	1.56(1.46;1.69)	<0.001
Previous PCI	1.09(0.96;1.23)	0.176			
Previous CABG	1.27(1;1.6)	0.053			
On pump CABG	1.1(1.02;1.19)	0.009			
Period of study (as compared to 1997-2002)			Period of study (as compared to 1997-2002)		
2003-2007	0.66(0.61;0.71)	<0.001	2003-2007	0.9(0.81;0.1)	0.041
2008-2012	0.41(0.37;0.45)	<0.001	2008-2012	0.83(0.75;0.91)	<0.001
2013-2017	0.28(0.25;0.32)	<0.001	2013-2017	0.7(0.64;0.78)	<0.001
			Hospital without CABG on site	0.87(0.81;0.93)	<.001
			Diabetes	1.54(1.4;1.7)	<.001

Table 2. Factors associated to in-hospital mortality. Stepwise logistic regression. CABG: coronary artery bypass grafting. PCI: percutaneous coronary intervention. COPD: chronic obstructive pulmonary disease. MI: myocardial infarction. NSTEMI: non-ST elevation acute coronary syndrome. PVD: peripheral vascular disease. CHF: congestive heart failure. CVD: cerebrovascular disease. CKD: chronic kidney disease.

	1998-2002	2003-2007	2008-2012	2013-2017	p _(TL)
Median number of hospitals/year					
(+)CABG(+)PCI	37(36;40)	44(42;44)	47(47;47)	48(45;50)	<0.001
(-)CABG(+)PCI	25(19;32)	61(54;62)	93(88;96)	96(70;99)	<0.001
Median number of procedures/center-year					
CABG	130.5(102;163)	103(73;145)	89(58;120)	74.5(49;109)	<0.001
PCI	148(58;249)	195(77;334)	185.5(71;344)	198(79;350)	<0.001
Mortality according to hospital volume of procedures					
Hospital Volume of CABG					
Low Volume	331/3871(8.6)	206/3053(6.8)	87/2406(3.6)	72/2077(3.5)	<0.001
Low-Intermediate	411/5511(7.5)	322/4671(6.9)	172/4276(4)	106/3680(2.9)	<0.001
Low-High	530/7149(7.4)	345/6984(4.9)	226/6449(3.5)	161/5495(2.9)	<0.001
High	469/9157(5.1)	352/9525(3.7)	265/8377(3.2)	217/8232(2.6)	<0.001
Hospital Volume of PCI					
Low Volume	18/3260(0.6)	31/6006(0.5)	45/7575(0.6)	61/7628(0.8)	0.049
Low-Intermediate	67/8159(0.8)	155/17227(0.9)	201/21343(0.9)	237/21622(1.1)	0.014
Low-High	172/15955(1.1)	426/33550(1.3)	685/45385(1.5)	700/45053(1.6)	<0.001
High	296/30872(1)	745/61926(1.2)	1226/84660(1.5)	1189/77549(1.5)	<0.001

Table 3. Number of hospitals and volume of procedures/hospital in each study period. Data is shown as n(%) or median and IQR. CABG: "Coronary Artery Bypass Grafting". PCI: "Percutaneous Coronary Intervention. (+)CABG(+)PCI: Hospitals with CABG and PCI: (-)CABG(+)PCI. Hospitals without CABG but with PCI.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1. Flow diagram. Selection of patients.

Figure 2. Number of procedures.

Figure 3. Non adjusted and adjusted in-hospital mortality. RAMR: Risk adjusted mortality rate.




Figure 1. Flow diagram. Selection of patients.

187x265mm (300 x 300 DPI)






Figure 2. Number of procedures.

189x143mm (300 x 300 DPI)



. Non adjusted and adjusted in-hospital mortality. RAMR: Risk adjusted mortality rate.

189x273mm (300 x 300 DPI)

Supplemental Material

Table 1. ICD9 and ICD10 codes

	ICD9	ICD10
CABG	36.1x	0210xxx,0211xxx,0212xxx,0213xxx
PCI	00.66, 36.03, 36.06, 36.07, 36.09	0270xxx, 0271xxx,0272xxx,0273xxx
Excluded Concomitant procedures	35.xx, 37.3x, 37.51, 38.44, 38.45, 39.1x, 39.2x, 39.3x and 37.90	027Fxxx, 027Gxxx, 02NFxxx, 02NGxxx, 02Vxxxx, 027Jxxx, 02NJxxx, 02Nxxxx, 02Rxxxx, 02Qxxxx, 028xxxx, 02Bxxxx, 02Cxxxx, 02Fxxxx, 02Hxxxx, 02Jxxxx, 02Kxxxx, 02Nxxxx, 02Pxxxx, 02Uxxxx, 02Wxxxx, 02Yxxxx, 025xxxx
AMI/STEACS	410.x1	I21.x9, I21.x1, I21.x, I21.4, I21.3, I21.9


CABG: coronary artery bypass grafting. PCI: percutaneous coronary intervention. AMI: acute myocardial infarction STEACS: ST elevation acute coronary syndrome

Table 2. Variables included in the model to predict risk adjusted mortality rates for CABG and PCI.

	Model to estimate RAMR after CABG	Model to estimate RAMR after PCI
Variables	Spanish region, Groups of hospitals according to the volume of CABG/year-center, COPD, Age ranges, Sex, Previous MI, NSTEMACS, PVD, CVD, Diabetes, CKD, Previous CABG, Previous PCI, Off-Pump, CHF	CABG on site Spanish region, Groups of hospitals according to the volume of PCI/year-center, COPD, Age ranges, Sex, Previous MI, NSTEMACS, PVD, CVD, Diabetes, CKD, Previous CABG, CHF
AUC	0.76 (95%CI 0.75;0.77)	0.8 (95%CI 0.8;0.81)

CABG: coronary artery bypass grafting. PCI: percutaneous coronary intervention. COPD: chronic obstructive pulmonary disease. MI: myocardial infarction. NSTEMACS: non-ST elevation acute coronary syndrome. PVD: peripheral vascular disease. CHF: congestive heart failure. CVD: cerebrovascular disease. CKD: chronic kidney disease. AUC Area Under the Curve.

Figure 1. Median Number of Procedures/Hospital- year.



Reporting checklist for quality improvement study.

Based on the SQUIRE guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SQUIRE reporting guidelines, and cite them as:

Ogrinc G, Davies L, Goodman D, Batalden P, Davidoff F, Stevens D. SQUIRE 2.0 (Standards for Quality Improvement Reporting Excellence): revised publication guidelines from a detailed consensus process

	Reporting Item	Page Number
Title		
	#1 Indicate that the manuscript concerns an initiative to improve healthcare (broadly defined to include the quality, safety, effectiveness, patientcenteredness, timeliness, cost, efficiency, and equity of healthcare)	2,3
Abstract		
	#02a Provide adequate information to aid in searching and indexing	2
	#02b Summarize all key information from various sections of the text using the abstract format of the intended publication or a structured summary such as: background, local problem, methods, interventions, results, conclusions	2
Introduction		
Problem description	#3 Nature and significance of the local problem	3

1	Available	#4	Summary of what is currently known about the problem, including	3
2	knowledge		relevant previous studies	
3				
4				
5	Rationale	#5	Informal or formal frameworks, models, concepts, and / or theories	3-4
6			used to explain the problem, any reasons or assumptions that were used	
7			to develop the intervention(s), and reasons why the intervention(s) was	
8			expected to work	
9				
10				
11	Specific aims	#6	Purpose of the project and of this report	3
12				
13				
14	Methods			
15				
16	Context	#7	Contextual elements considered important at the outset of introducing	3
17			the intervention(s)	
18				
19				
20	Intervention(s)	#08a	Description of the intervention(s) in sufficient detail that others could	4
21			reproduce it	
22				
23				
24	Intervention(s)	#08b	Specifics of the team involved in the work	1,7
25				
26	Study of the	#09a	Approach chosen for assessing the impact of the intervention(s)	3,4
27	Intervention(s)			
28				
29				
30	Study of the	#09b	Approach used to establish whether the observed outcomes were due to	3,4
31	Intervention(s)		the intervention(s)	
32				
33				
34	Measures	#10a	Measures chosen for studying processes and outcomes of the	3,4
35			intervention(s), including rationale for choosing them, their operational	
36			definitions, and their validity and reliability	
37				
38				
39	Measures	#10b	Description of the approach to the ongoing assessment of contextual	3,4
40			elements that contributed to the success, failure, efficiency, and cost	
41				
42				
43	Measures	#10c	Methods employed for assessing completeness and accuracy of data	3,4
44				
45	Analysis	#11a	Qualitative and quantitative methods used to draw inferences from the	4
46			data	
47				
48				
49	Analysis	#11b	Methods for understanding variation within the data, including the	4
50			effects of time as a variable	
51				
52				
53	Ethical	#12	Ethical aspects of implementing and studying the intervention(s) and	3
54	considerations		how they were addressed, including, but not limited to, formal ethics	
55			review and potential conflict(s) of interest	
56				
57				
58	Results			
59				
60				

1		#13a	Initial steps of the intervention(s) and their evolution over time (e.g.,	4, 5
2			time-line diagram, flow chart, or table), including modifications made	
3			to the intervention during the project	
4				
5				
6		#13b	Details of the process measures and outcome	4,5, 10,
7				12
8				
9				
10		#13c	Contextual elements that interacted with the intervention(s)	4,5, 10,
11				12
12				
13				
14		#13d	Observed associations between outcomes, interventions, and relevant	4,5, 10,12
15			contextual elements	
16				
17				
18		#13e	Unintended consequences such as unexpected benefits, problems,	4,5,10,12
19			failures, or costs associated with the intervention(s).	
20				
21				
22		#13f	Details about missing data	7
23				
24	Discussion			
25				
26	Summary	#14a	Key findings, including relevance to the rationale and specific aims	5
27				
28	Summary	#14b	Particular strengths of the project	2,5
29				
30				
31	Interpretation	#15a	Nature of the association between the intervention(s) and the outcomes	5,6
32				
33	Interpretation	#15b	Comparison of results with findings from other publications	5,6
34				
35	Interpretation	#15c	Impact of the project on people and systems	5,6
36				
37				
38	Interpretation	#15d	Reasons for any differences between observed and anticipated	5,6
39			outcomes, including the influence of context	
40				
41				
42	Interpretation	#15e	Costs and strategic trade-offs, including opportunity costs	n/a
43				
44	Limitations	#16a	Limits to the generalizability of the work	7
45				
46	Limitations	#16b	Factors that might have limited internal validity such as confounding,	7
47			bias, or imprecision in the design, methods, measurement, or analysis	
48				
49				
50	Limitations	#16c	Efforts made to minimize and adjust for limitations	7
51				
52	Conclusion	#17a	Usefulness of the work	5,6
53				
54	Conclusion	#17b	Sustainability	5,6
55				
56	Conclusion	#17c	Potential for spread to other contexts	5,6
57				
58				
59				
60				

1	Conclusion	#17d	Implications for practice and for further study in the field	5,6
2				
3	Conclusion	#17e	Suggested next steps	6
4				
5				
6	Other			
7	information			
8				
9	Funding	#18	Sources of funding that supported this work. Role, if any, of the	7
10			funding organization in the design, implementation, interpretation, and	
11			reporting	
12				
13				
14				

Notes:

- 13b: 4,5, 10, 12
- 13c: 4,5, 10, 12 The SQUIRE 2.0 checklist is distributed under the terms of the Creative Commons Attribution License CC BY-NC 4.0. This checklist was completed on 20. October 2020 using <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)

BMJ Open

Retrospective cohort analysis of Spanish national trends of coronary artery bypass grafting and percutaneous coronary intervention from 1998 to 2017

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-046141.R1
Article Type:	Original research
Date Submitted by the Author:	03-Feb-2021
Complete List of Authors:	CARNERO ALCAZAR, MANUEL; Hospital Clínico Universitario San Carlos Instituto Cardiovascular, Cardiac Surgery Hernandez-Vaquero, Daniel ; Hospital Universitario Central de Asturias, Cardiac Surgery Cubero-Gallego, Hector; Hospital del Mar, Cardiology. Unit of Interventional Cardiology. Lopez Menendez, Jose; Hospital Ramon y Cajal, Cardiac Surgery Piñon, Miguel; Alvaro Cunqueiro Hospital, Cardiac Surgery Albors Martin, Jose; Hospital Universitario del Vinalopó, Cardiac Surgery Cuerpo Caballero, Gregorio; Hospital General Universitario Gregorio Marañón, Cardiac Surgery Cobiella Carnicer, Javier; Hospital Clínico Universitario San Carlos Instituto Cardiovascular, Cardiac Surgery Villamor, Cristina; Hospital Clinico Universitario San Carlos, Internal Medicine Forteza, Alberto; Puerta del Hierro University Hospital of Majadahonda, Cardiac Surgery Pascual, Isaac; Hospital Universitario Central de Asturias, Cardiology. Unit of Interventional Cardiology. Maroto Castellanos, Luis; Hospital Clínico Universitario San Carlos Instituto Cardiovascular, Cardiac Surgery
Primary Subject Heading:	Cardiovascular medicine
Secondary Subject Heading:	Epidemiology, Public health
Keywords:	Coronary heart disease < CARDIOLOGY, Cardiac Epidemiology < CARDIOLOGY, PUBLIC HEALTH, Cardiac surgery < SURGERY, Coronary intervention < CARDIOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **1 Title: Retrospective cohort analysis of Spanish national trends of coronary artery bypass**
4 **2 grafting and percutaneous coronary intervention from 1998 to 2017.**

5 3
6 4 **Authors:**

7 5
8 6 Manuel Carnero-Alcázar(1), Daniel Hernandez-Vaquero(2), Héctor Cubero-Gallego (3), José
9 7 López-Menéndez(4), Miguel Piñón(5), José Albors-Martín(6), Gregorio Cuerpo-Caballero(7),
10 8 Javier Cobiella-Carnicer(1), Cristina Villamor (8), Alberto Forteza (9), Isaac Pascual (10),
11 9 Luis C Maroto-Castellanos(1)

12 10
13 11 1.Department of Cardiac Surgery. Hospital Clínico San Carlos. CardioRed1. Madrid. Spain.
14 12 2.Department of Cardiac Surgery. Hospital Central de Asturias. Oviedo. Spain.
15 13 3.Unit of Interventional Cardiology. Department of Cardiology. Hospital del Mar. Barcelona,
16 14 Spain.
17 15 4. Department of Cardiac Surgery. Hospital Ramón y Cajal. Madrid. Spain.
18 16 5. Department of Cardiac Surgery. Hospital Álvaro Cunqueiro. Vigo. Spain.
19 17 6. Department of Cardiac Surgery. Hospital del Vinalopó. Alicante. Spain.
20 18 7. Department of Cardiac Surgery. Hospital Gregorio Marañón. Madrid. Spain.
21 19 8. Department of Internal Medicine. Hospital Clínico San Carlos. Madrid. Spain.
22 20 9. Department of Cardiac Surgery. Hospital Puerta de Hierro. Majadahonda. Spain.
23 21 10. Unit of Interventional Cardiology. Department of Cardiology. Hospital Universitario
24 22 Central de Asturias. Oviedo, Spain.
25 23
26 24
27 25

28 26 **Corresponding author:** Manuel Carnero Alcázar. Dpt. of Cardiac Surgery. Hospital Clínico
29 27 San Carlos. Plaza Cristo Rey s/n.28040. Madrid. Spain. Email: E-mail:
30 28 mcarneroalcazar@gmail.com Tlph: +34646773287
31 29

32 30
33 31 **Structured abstract & article summary: 358**

34 32 **Abstract: 270**

35 33 **Text: 3340**

36 34 **References: 971**

37 35 **Tables and Figures: 922**
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 36 **Article Summary**

4 37
5 38 **Abstract**
6 39

7 40 **Introduction.** Spain is one of the countries with the lowest rates of revascularization and highest
8 41 ratio of percutaneous coronary intervention (PCI) to coronary artery bypass grafting (CABG).

9 42 **Objectives.** To investigate the changes and trends in the two revascularization procedures
10 43 between 1998 and 2017 in our country.

11 44 **Design.** Retrospective cohort study. Analysis of in-hospital outcomes.

12 45 **Setting.** Minimum Basic Dataset from the Spanish National Department of Health: mandatory
13 46 database collecting information of patients who are attended in the Spanish public National Health
14 47 System.

15 48 **Participants.** 603,976 patients who underwent isolated CABG or PCI in the Spanish National
16 49 Health System. The study period was divided in four 5-year intervals. Patients with acute
17 50 myocardial infarction on admission were excluded.

18 51 **Primary and Secondary Outcomes:** We investigated the volume of procedures nationwide, the
19 52 changes of the risk profile of patients and in-hospital mortality of both techniques.

20 53 **Results.** We observed a 2.2-fold increase in the rate of any type of myocardial
21 54 revascularization/million inhabitants-year: 357(1998) to 776(2017). 93,682(15.5%) had a
22 55 coronary surgery. PCI to CABG ratio rose from 2.2 (1998-2002) to 8.1 (2013-2017). Charlson's
23 56 index increased by 0.8 for CABG and 1 for PCI. The median annual volume of PCI/hospital
24 57 augmented from 136 to 232, while the volume of CABG was reduced from 137 to 74. In the two
25 58 decades, we detected a significant reduction of CABG in-hospital mortality (6.5% Vs
26 59 2.6%, $p<0.001$) and a small increase in PCI (1.2% Vs 1.5%, $p<0.001$). Risk adjusted mortality rate
27 60 was reduced for both CABG (1.51 Vs 0.48, $p<0.001$), and PCI (1.42 Vs. 1.05, $p<0.001$).

28 61 **Conclusion.** We detected a significant increase in the volume of revascularizations (particularly
29 62 PCI) in Spain. Risk-adjusted in-hospital mortality was significantly reduced
30 63

31 64 **Strengths and limitations.**

- 32 65
- 33 66 • This is the first study to investigate the nationwide changes and trends in coronary
 - 34 67 revascularization in Spain during the past two decades.
 - 35 68 • It was based on a very large and detailed administrative database which included most of
 - 36 69 the episodes of patients who have been admitted to any public NHS hospital between 1998-2017.
 - 37 70 • Follow up information is not available
 - 38 71 • The analysis might be biased by administrative information coding errors and missings.
 - 39 72 • However, no other source of information allows to perform a long-term nationwide
 - 40 73 investigation like this.
 - 41 74
 - 42 75
 - 43 76
 - 44 77
 - 45 78
 - 46 79
 - 47 80
 - 48 81
 - 49 82
 - 50 83
 - 51 84
 - 52 85
 - 53 86
 - 54 87
 - 55 88
 - 56 89
 - 57 90
 - 58 91
 - 59 92
 - 60 93

74 INTRODUCTION

75
76 Surgical and percutaneous myocardial revascularization have demonstrated to improve
77 symptoms and life expectancy in patients with advanced coronary artery disease. In the vast
78 majority of patients with ST-elevation acute coronary syndrome, percutaneous coronary
79 intervention (PCI) is the preferred strategy(1). However, in chronic stable angina or non-ST
80 elevation acute coronary syndromes, the choice between PCI and coronary artery bypass grafting
81 (CABG) depends on multiple factors. In this scenario, the best therapeutic option for each patient
82 must be decided(1,2) by a multidisciplinary “Heart Team”.

83 Many authors have investigated large national registries and analyzed the changes of both
84 techniques over time and the distribution of CABG and PCI across different regions and countries
85 (3-6). Spain is, according to the OECD(6), one of the European countries with the lowest rates of
86 revascularization and the one with the highest ratio of PCI to CABG. The causes of the magnitude
87 of this disbalance have never been studied in depth. Moreover, there is no robust evidence on the
88 evolution of the two techniques in terms of their results and variability, nor the risk profile of
89 CABG and PCI patients in the Spanish National Health System (NHS).

90 In our country, there are no patient-level clinical registries specifically dedicated to
91 patients with coronary artery disease undergoing myocardial revascularization. The Spanish
92 Society of Thoracic and Cardiovascular Surgery and the Spanish Society of Cardiology annually
93 report the national volumes and outcomes of CABG and PCI (7,8). However, these reports are
94 based on voluntary, aggregated and unaudited information submitted by hospitals. On the other
95 hand, the healthcare centers of the Spanish NHS have to report the administrative information of
96 all admitted patients to a mandatory nationwide registry: The Minimum Basic Dataset (MBDS)
97 from the Department of Health. The MBDS is a public open access database which stores
98 individual and anonymized data from all discharge reports from all the NHS episodes, coded
99 according to the International Classification of Diseases (ICD). Despite the fact that the use of
100 non-specific administrative sources, such as this one, for the analysis of clinical indicators in the
101 field of cardiology is controversial(9), different studies based on the MBDS have validated its
102 usefulness to analyze the results of clinical processes in Spain(10-14)

103 We set out to study the evolution of CABG and PCI in Spain between 1998 and 2017
104 with the information obtained from the MBDS of the Department of Health of our country.
105 Specifically, we analyzed the volume of CABG and PCI, the changes in the risk profile of patients
106 and hospital mortality in the two revascularization strategies. It was not the objective of this study
107 to compare the results of both techniques, taking into account that they have different indications
108 and that follow-up information is not available.

109 MATERIALS AND METHODS

110 *Sources of information and patient selection*

111
112
113
114 Data was obtained from the MBDS from the Department of Health of Spain. This research
115 was carried out according to the STROBE (Strengthening the Reporting of OBServational studies
116 in Epidemiology) recommendations. This study was approved by the Institutional Review Board
117 and Ethics Committee at Hospital Clínico San Carlos (Madrid,Spain).

118 The patient selection algorithm can be seen in Figure 1. We investigated all the outpatient
119 or hospitalization episodes of the Spanish NHS from 1998 to 2017 in which a CABG or PCI
120 procedure had been carried out. Those episodes during which, patients underwent concomitant
121 procedures were excluded (See supplementary Table 1 ICD9 and ICD10 codes).

122 Likewise, all episodes with an acute myocardial infarction/acute coronary syndrome with
123 ST segment elevation as the primary diagnosis on admission (See supplementary Table 1) were
124 excluded, as those with both types of revascularization. In addition, to avoid possible coding
125 errors, patients younger than 18 or older than 100-year-old, patients operated on CABG in centers
126 without CABG or who underwent PCI in centers without PCI were also discarded. Patients
127 discharged alive earlier than two days after CABG were also considered as coding errors. The
128 episodes corresponding to patients who were transferred to another center and consecutive

1
2
3 129 planned revascularizations episodes were consolidated into a single episode(14). Each episode
4 130 corresponds to a single patient, but a patient might have more than one episode. Given that we
5 131 analyzed in-hospital outcomes, different consolidated episodes will be considered as different
6 132 patients for the purpose of this study.

7 133 The full period of time (1998-2017) was divided in four 5-year intervals (1998-2002,
8 134 2003-2007, 2008-2012 and 2013-2017).

9 135

10 136 *Patient and Public Involvement*

11 137

12 138 No patient was actively involved in the study. Information regarding the delivered
13 139 healthcare to the patients included in this investigation was obtained deidentified from the Spanish
14 140 Department of Health

15 141

16 142 *National volume of revascularization procedures and risk profile of the patients*

17 143

18 144 We investigated the absolute number of CABG and PCI per year, the number of
19 145 procedures per million of inhabitants and the changes in the PCI/CABG ratio. Further analyses to
20 146 investigate the trends in the indexed volume of each type of procedure were also performed
21 147 according to sex and age. To estimate the nationwide population, data was extracted from the
22 148 National Institute of Statistics(15).

23 149

24 150 Healthcare centers were classified according to the volume of procedures per year. Thus,
25 151 for both CABG and PCI, hospitals were divided into four groups according to the quartile of the
26 152 volume of PCI or CABG interventions that they performed in each year: Low volume (quartile
27 153 1), Low-Intermediate Volume (quartile 2), High-Intermediate Volume (quartile 3) and High
28 154 Volume (quartile 4) .

29 155

30 156 Patients were classified into four groups according to their age ($\leq 60, >60$ & $\leq 70, >70$ &
31 157 ≤ 80 , and >80 -year-old). We analyzed the evolution of the prevalence of various comorbidities
32 158 Age-modified Charlson's Index was calculated (16,17). In addition, the individual components
33 159 of this score (previous history of myocardial infarction, kidney disease, diabetes, ...) and other
34 160 procedural variables were analyzed throughout the study period (see Table 1).

35 161

36 162 *Mortality*

37 163

38 164 We analyzed in hospital non-adjusted and adjusted mortality for PCI and CABG and its
39 165 changes over the study period.

40 166

41 167 *Statistical Analysis.*

42 168

43 169 Categorical variables were represented with absolute and relative frequencies (%) and
44 170 were compared with the chi-squared test. The normality of the quantitative variables was analyzed
45 171 with PP- plots, and they were expressed with mean and standard deviation or median and
46 172 interquartile range. Imputation was not made for missing values. Statistics were estimated using
47 173 available data. Quantitative variables were compared among the periods of the study with an
48 174 analysis of variance or non-parametric comparison of medians. Contrasts were performed to
49 175 investigate the presence of a linear trends (LT). The relative risk reduction (RRR) and odds ratio
50 176 (OR) were used to represent the strength of association between different variables and mortality.

51 177

52 178 We investigated factors associated to mortality for each type of revascularization. For this
53 179 purpose, we created multivariable models including variables with theoretical value and variables
54 180 related to mortality (statistical significance $p < 0.1$) in an univariable analysis. The best models
55 181 were selected based on the value of the Akaike information criterion, R^2 and their area under the
56 182 curve.

57 183

58 184 Subsequently, we estimated 2 new models to predict mortality after PCI and CABG,
59 185 respectively, excluding the time period. We divided the observed mortality in each year for PCI
60 186 and CABG by that expected according to the corresponding model. In this way, we analyzed the
61 187 evolution of risk- adjusted mortality rate (RAMR) over time. (14).

1
2
3 184 Statistical analysis was performed with Stata v 15.0 (StataCorp. 2017. Stata Statistical
4 185 Software:Release 15.College Station,TX: StataCorp LLC.)
5 186

6 187 **RESULTS**

7 188 8 189 *Study Population*

9 190
10 191 Almost one million (977,797) episodes of CABG or PCI were included in the study.
11 192 Thirty eight percent (373,831) were excluded, and 603,967 were considered for the purpose of
12 193 this study (Supplementary Table 2 and Figure 1). Of these, 93,682(15.5%) had CABG and
13 194 5103,294(84.5%) PCI. There was a linear increase ($p_{LT}<0.001$) in the PCI/CABG ratio: 1998-
14 195 2002: 2.2(69% PCI vs. 31% CABG), 2003-2007:5(83.3% PCI Vs. 16.7% CABG), 2008-2012:7.6
15 196 (88.3% PCI Vs. 11.7% CABG), and 2013-2017:8.1(89% PCI Vs. 11% CABG) (Table 1). In the
16 197 general sample, an increase in the number of revascularizations was observed, mainly due to a
17 198 higher number of PCI and a drop in CABG. (Figure 2A). We observe relevant differences in the
18 199 volume of procedures by sex. Overall, more PCI and CABG were performed in men than in
19 200 women, but the difference increased more markedly in PCI (Figure 2B). Regarding the type of
20 201 procedure by age range, PCI increased in all age ranges, although the increase was more
21 202 pronounced in those over 60 years of age. On the contrary, CABG significantly decreased among
22 203 those over 70 years of age and experienced a slight decrease in the younger population strata
23 204 (Figure 3). Absolute number of procedures and according to type of coronary syndrome is shown
24 205 in supplementary figures 2 and 3.

25 206 The risk profile of patients worsened throughout the study period (table 1). In PCI and
26 207 CABG groups, we observed a higher mean age and a greater prevalence of risk factors such as
27 208 previous myocardial infarction, heart failure, peripheral vascular disease, diabetes or chronic
28 209 obstructive pulmonary disease (COPD). Consequently, Charlson's Index rose up from 2.7 to
29 210 3.5($p_{LT}<0.001$) in CABG and from 2.6 to 3.6 ($p_{LT}<0.001$) in PCI (Table 1 and Supplementary
30 211 Figure 4).

31 212 We detected a significant growth of PCI in centers without CABG: 1998-2002 (17.4%)
32 213 2013-2017 (41.1%) ($p_{LT}<0.001$). The proportion of patients who had three or more coronary
33 214 arteries revascularized was higher in the CABG group (40.5% Vs 7.1%, $p<0.001$). We observed a
34 215 linear increase in the use of bilateral internal thoracic arteries (8% Vs. 23.6 %, $p_{LT}<0.001$), and
35 216 off-pump CABG (31.3% Vs. 34.2% $p_{LT}<0.001$) from the first to the last period. Similarly, an
36 217 increase in drug eluting stents and a decrease of bare metal stents was observed among PCI
37 218 patients ($p_{LT}<0.001$). The number of outpatient percutaneous procedures was small, but increased
38 219 in the las two periods (see table 1).

39 220 We observed a growth of episodes of patients with diabetes and an increase of
40 221 percutaneous procedures in this subset. Specific information on patients with diabetes can be
41 222 found in Supplementary table 3.
42 223
43 224

44 225 *Mortality*

45 226
46 227 Among patients undergoing CABG, a reduction in non-adjusted in-hospital mortality
47 228 was observed between 1998 and 2017: 6.5% Vs. 2.6% ($p_{LT}<0.001$; RRR -60%, 95%CI -64.8%;
48 229 -55.2%). Mortality among patients undergoing PCI raised slightly from 1.2% to 1.5% ($p_{LT}<0.001$;
49 230 RRR +25%, 95%CI 22.3%;27.6%) (Figure 4A).

50 231 Table 2 shows factors independently associated to in-hospital mortality after CABG or
51 232 PCI. Most of the factors increased mortality regardless of the type of revascularization (COPD,
52 233 age, previous infarction, heart failure, etc...). The effect of some variables changed depending
53 234 on the type of revascularization such as the hospital volume of procedures and period of study.
54 235 PCI mortality in centers without CABG was lower than in centers with CABG on site (OR
55 236 0.86,95%CI 0.8; 0.92, $p<0.001$) (more information can be found in Supplementary material)

56 237 Information regarding the estimation of RAMR is shown in Supplementary tables 4 and
57 238 5. A decrease in RAMR was detected in both CABG and PCI patients. In the case of coronary
58
59
60

239 surgery, the RAMR decreased from 1.51 to 0.48($p_{LT} < 0.001$), and in the case of PCI from 1.42 to
240 1.05 ($p_{LT} < 0.001$) between 1998 and 2017 respectively (see Figure 4B).

241

242 *Volume of activity and mortality by center*

243

244 The number of centers with CABG and PCI on site grew from 37 (1998-2002) to 48
245 (2013-2017)($p_{LT} < 0.001$)(Supplementary Material : Table 6 and Figure 5). The number of centers
246 with PCI but without CABG on site increased from 25 (1998) to 96 (2017). We observed a higher
247 median volume of PCI per center from 136 to 232($p_{LT} < 0.001$) and a decrease in CABG from 137
248 to 74 CABG($p_{LT} < 0.001$) between 1998 and 2017. (Supplementary material). The volume of
249 interventions was independently associated to a lower in-hospital mortality for CABG and a
250 higher mortality after PCI (see table 2)

251

252 DISCUSSION

253

254 Between 1998 and 2017, in Spain, the volume of revascularizations in patients without
255 ST elevation myocardial infarction increased to 776/million inhabitants (See Figure 2). However,
256 these rates are very low as compared to other countries. For example, in the United States, the
257 number of CABG per million inhabitants in 2007-2008 was 1,081/year, while that of PCI was
258 3,667/year(18). In Germany, in 2013, the proportion of revascularizations per 100,000 inhabitants
259 was three times higher than in Spain(6). Although the differences can be explained by the lower
260 prevalence of coronary heart disease in our country, there are other factors that may influence
261 such as a greater difficulty in accessing the healthcare system for patients or a less frequent
262 indication for revascularization.

263

264 In addition, there was, over the past 20 years, a 27.7% reduction in the volume of CABG
265 (5506 in 1998 Vs 3872 in 2017) and a 3.7-fold increase of PCI volume (8735 in 1998 Vs 32272
266 in 2017). During such a long period of time, the indications for CABG and PCI have varied,
267 mainly in patients with stable 1 or 2-vessel coronary artery disease, with percutaneous
268 revascularization being the most frequently indicated nowadays. In patients with left main or
269 three-vessel disease, the indication for PCI has also gained strength, although with less intensity.
270 These changes have been mainly due to the development of new percutaneous devices and the
271 optimization of medical treatment. (1,19). Even so, different studies have consistently continued
272 to detect the benefit of CABG in patients with more complex coronary disease (2,20).

272

273 The PCI/CABG ratio in the last period of the study was 8.1. In the 2015 "*Health at a*
274 *Glance*" report, the PCI/CABG ratio was 7.3 in Spain, close to that observed in this study and
275 more than double the average of the countries included in that report: 3.55(6). Similar changes
276 have happened in other countries. For example, the analysis of the US National Inpatient Sample
277 registry found a decline in the volume of CABG of 116% between 1998 and 2015(21) and 14%
278 between 2001 and 2007 with a stabilization of the volume of PCI(18). The New York State
279 registry detected an increase in the PCI/CABG ratio between 1994 and 2008 from 1.12 to 5.14(5).
280 The ratio observed in the present study, however, is difficult to compare since we have excluded
281 revascularizations among patients with acute myocardial infarction which were considered in
282 other reports (6). Therefore, the PCI to CABG ratio in Spain might be even higher. This large
283 difference in our country may be due to several factors such as difficulties in accessing one of the
284 therapies, poor adherence to therapeutic recommendations, underindication of revascularization,
285 or the characteristics of coronary heart disease in the Spanish population being different from
286 those in other developed countries. Furthermore, we detected large and increasing differences
287 between men and women depending on the type of revascularization (see figure 2), which
288 probably denotes a limited access of women to the healthcare system.

288

289 A significant worsening of the risk profile has been observed for both PCI and CABG
290 patients: 14% raise in the prevalence of diabetes, 6-fold increase of patients with severe chronic
291 kidney disease or COPD by 2 (see Table 1). In general, the poorer risk profile of patients is
292 consistent with a progressive aging and a higher prevalence and severity of cardiovascular risk
293 factors observed in Spain and other countries(22- 24). Despite the conflicting evidence on the
294 benefit of off pump CABG or multiple arterial grafts revascularization, in Spain there has been

294 an increase in the number of patients operated on with two or more internal thoracic arterial grafts
295 (8% in the first period Vs. 23.6% between 2013 and 2017($p_{LT}<0.001$)) or off pump (31.3% Vs
296 34.2% in the first and last period respectively, $p_{LT}<0.001$)(25,26). Regarding PCI,
297 revascularizations with drug eluting stents grew as bare metal stents less became less frequently
298 used.

299 Mortality after CABG in Spain has decreased from 6.5% in 1998 to 2.6% in 2017 and is
300 now similar to that of other countries (22). The strong reduction of mortality is a common finding
301 too: for example, the registry for New South Wales detected a reduction of in hospital mortality
302 after CABG of 30% between 2000 and 2013(27). A significant 4- fold reduction in risk-adjusted
303 mortality was observed too between 1998 and 2017 (0.44) (1.55 to 0.44($p_{LT}<0.001$)).

304 Hospital mortality after PCI in Spain was similar to that of other developed
305 countries(28,29), and slightly grew throughout the series. When adjusting for patient
306 comorbidities and other confounding factors, the RAMR was reduced by almost 40% (1.42 to
307 1.05($p_{LT}<0.001$)).

308 We have detected a fourfold growth of the number of centers that perform PCI without
309 CABG (see Supplementary Table 6). Between 2013 and 2017, 41.1% of the patients treated with
310 PCI were revascularized in a center without coronary surgery. In addition, there has been a very
311 significant reduction in the median number of CABG procedures per center between the first and
312 last period of the study (130.5 Vs 75.5, $p_{LT}<0.001$). This volume of interventions per center is
313 different from that reported by Goicolea et al. (15) who detected a mean number of CABG
314 procedures of 95/year between 2013 and 2015. Goicolea et al. misclassified procedures such as
315 combined surgery of the aorta, pericardium, ventricular remodeling or cardiac arrhythmias as
316 isolated coronary surgery interventions, which can explain the differences. In any case, the
317 volume of CABG or PCI per center in Spain is very low. For example, in Europe, hospitals with
318 an intermediate volume of CABG perform between 125 and 450 procedures per year(30) and the
319 EACTS/ESC Myocardial Revascularization Guidelines recommend a minimum of 200 isolated
320 CABG interventions to maintain viable coronary surgery programs(1).

321 There is an important relationship between the volume of CABG per center and in-
322 hospital mortality, such that as the volume of the centers increases, mortality decreases. On the
323 contrary, mortality after PCI increases as the volume of interventions increases (Table 2 and
324 Supplementary Material). The latter can be explained by the fact that patients referred to centers
325 with greater activity may have anatomical characteristics or comorbidities that confer a greater
326 risk, and which have not been adequately contemplated in this study (i.e.: left man disease,
327 severely calcified coronary arteries, poor left ventricular function...).

328 329 *Conclusions*

330
331 From 1998 to 2017 there has been a significant increase in the volume of
332 revascularizations in Spain. This growth has been uneven, with more PCI and a gradual reduction
333 in CABG. Risk-adjusted mortality has been significantly reduced in both arms, although the
334 reduction has been particularly pronounced among surgically revascularized patients. Finally, in
335 Spain, there is not an adequate balance between the volume of revascularizations and the number
336 of hospitals, with centers with a low number of CABG procedures and a great proportion of
337 hospitals with PCI programs but without CABG onsite.

338 339 *Limitations*

340
341 These conclusions have to be taken with caution due to possible coding biases and others
342 inherent to administrative databases analyses. Beyond a real change, the variation in the
343 prevalence of comorbidities can be also partially explained by changes and errors in coding
344 throughout de study period. Surgical turndowns are known to have higher risk despite risk
345 adjustment, but they could not be identified in this dataset. We could not estimate operative or
346 cardiovascular risks according to validated clinical scores in cardiac surgery or cardiology (such
347 as EuroSCORE, Framingham Risk Score or NCDR CathPCI Mortality risk) given that the items

1
2
3 348 of these scores are not available in the MBDS. The MBDS does not contain information on private
4 349 activity in Spain.
5 350
6 351

7 352 **Footnotes:**

8 353 **Author Contributions:** MCA, DHV, HCG, LCMC, JLM, contributed to developing the design
9 354 of the study. MCA and LCMC requested the information from the Spanish Department of Health.
10 355 MCA, MP, JAM, CV, IP and GCC contributed to interpreting the data. MCA, JCC, DVH
11 356 performed the statistical analysis. AF and LCMC contributed to the critical review of the paper.
12 357 MCA is the guarantor of this work and assumes full responsibility for the conduct of the study

13 358 **Funding Statement:**

14 359 This research received no grant from any funding agency in the public, commercial or not-for-
15 360 profit sectors

16 361 **Competing interests:** None.

17 362 Patient consent for publication: Not required

18 363 **Ethics approval:** This study was approved by the Institutional Review Board and Ethics
19 364 Committee at Hospital Clínico San Carlos (Madrid)

20 365 **Data availability statement:** Data was provided deidentified by the *Unit of Health Care*
21 366 *Information and Statistics* (Spanish Department of Health), which stores securely the information
22 367 in their remote servers. This information is public and was provided only for investigation
23 368 purposes.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References:

1. Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. *Eur Heart J*.2019;40:87-165.
2. Mohr FW, Morice MC, Kappetein AP, Feldman TE, Ståhle E, Colombo A, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomized, clinical SYNTAX trial. *Lancet*.2013;381:629–38.
3. Blumenfeld O, Na'amnih W, Shapira-Daniels A, Lotan C, Shohat T, Shapira OM. Trends in Coronary Revascularization and Ischemic Heart Disease-Related Mortality in Israel. *J Am Heart Assoc*.2017;6:e004734.
4. Epstein AJ, Polsky D, Yang F, Yang L, Groeneveld PW. Coronary revascularization trends in the United States, 2001-2008. *JAMA*.2011;305:1769-76.
5. Ko W, Tranbaugh R, Marmur JD, Supino PG, Borer JS. Myocardial Revascularization in New York State: Variations in the PCI-to-CABG Ratio and Their Implications. *J Am Heart Assoc*.2012;1:e001446.
6. Health at a Glance: Europe 2016. State Of Health In The Eu Cycle. Available at: https://ec.europa.eu/health/sites/health/files/state/docs/health_glance_2016_rep_en.pdf. Accessed April 28,2020.
7. Cuerpo G, Carnero M, Hornero Sos F, Polo ML, Centella Hernandez T, Gascón P, et al. Cirugía cardiovascular en España en el año 2018. Registro de intervenciones de la Sociedad Española de Cirugía Torácica-Cardiovascular. *Cir Cardiovasc*.2019;26:248-64.
8. Cid Álvarez AB, Rodríguez Leor O, Moreno R, Pérez de Prado A. Registro Español de Hemodinámica y Cardiología Intervencionista. XXVII Informe Oficial de la Sección de Hemodinámica y Cardiología Intervencionista de la Sociedad Española de Cardiología (1990-2017). *Rev Esp Cardiol*.2018;71:1036-46.9. Mack MJ, Herbert M, Prince S, Dewey TM, Magee MJ, Edgerton JR. Does reporting of coronary artery bypass grafting from administrative databases accurately reflect actual clinical outcomes?. *J Thorac Cardiovasc Surg*.2005;129:1309–17.
10. Íñiguez Romo A, Bertomeu Martínez V, Rodríguez Padial L, Anguita Sanchez M, Ruiz Mateas F, Hidalgo Urbano R, et al. The RECALCAR Project. Healthcare in the Cardiology Units of the Spanish National Health System, 2011 to 2014. *Rev Esp Cardiol (Engl Ed)*.2017;70:567-575.
11. Rodríguez-Padial L, Bertomeu V, Elola FJ, Anguita M, Fernandez Lozano I, Sila L, et al. Quality improvement Strategy of the Spanish Society of Cardiology: The RECALCAR Registry. *J Am Coll Cardiol*.2016;68:1140-2.
12. Bertomeu V, Cequier Á, Bernal JL, Alfonso F, Anguita M, Barrabés JA, et al. In-hospital mortality due to acute myocardial infarction. relevance of type of hospital and care provided. RECALCAR study. *Rev Esp Cardiol(Engl Ed)*.2013; 66:935-42.
13. Gutacker N, Bloor K, Cookson R, Garcia-Armesto S, Bernal-Delgado E. Comparing hospital performance within and across countries: an illustrative study of coronary artery bypass graft surgery in England and Spain. *Eur J Public Health*.2015;25 Suppl 1:28–34.
14. Goicolea Ruigómez FJ, Elola FJ, Durante-López A, Fernández Pérez C, Bernal JL, Macaya C. Coronary artery bypass grafting in Spain. Influence of procedural volume on outcomes. *Rev Esp Cardiol (Engl Ed)*.2020[Epub ahead of print].
15. INEbase [Internet]. Madrid: Instituto Nacional de Estadística (Spain); [cited 2019, July, 20]. Available from: <http://www.ine.es/>.
16. Charlson ME, Szatrowski TP, Peterson J, Gold J. Validation of combined comorbidity index. *J Clinical Epidemiol*.1994;47:1245-51.
17. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, et al. Validation of the combined comorbidity index of Charlson and Elixhauser to predict 30-day mortality across ICD 9 and ICD 10. *Med Care*.2018;56:812.
18. Epstein AJ, Polsky D, Yang F, Yang L, Groeneveld PW. Coronary Revascularization trends in the United States:2001-2008. *JAMA*.2011;305:1769–1776.

- 1
2
3 424 19. Stephan Windecker, Philippe Kolh, Fernando Alfonso, Jean-Philippe Collet, Jochen Cremer,
4 425 Volkmar Falk, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task
5 426 Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the
6 427 European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special
7 428 contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI).
8 429 *Eur Heart J.* 2014;35:2541-619.
- 9 430 20. Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, et al. Strategies for
10 431 multivessel revascularization in patients with diabetes. *N Engl J Med.* 2012;367:2375-84.
- 11 432 21. Becker ER, Granzotti AM. Trends in In-hospital Coronary Artery Bypass Surgery Mortality
12 433 by Gender and Race/ Ethnicity –1998-2015: Why Do the Differences Remain?. *J Natl Med*
13 434 *Assoc.* 2019;111:527-539.
- 14 435 22. Cornwell LD, Omer S, Rosengart T, Holman WL, Bakaeen FG. Changes over time in risk
15 436 profiles of patients who undergo coronary artery bypass graft surgery: the Veterans Affairs
16 437 Surgical Quality Improvement Program (VASQIP). *JAMA Surg.* 2015;150:308-15
- 17 438 23. Beckmann A, Meyer R, Lewandowski J, Markewitz A, Harringer W. German Heart Surgery
18 439 Report 2018: The Annual Updated Registry of the German Society for Thoracic and
19 440 Cardiovascular Surgery. *Thorac Cardiovasc Surg.* 2019;67:331-344.
- 20 441 24. Vora AN, Dai D, Gurm H, Amin AP, Messenger JC, Mahmud E, et al. Temporal Trends in
21 442 the Risk Profile of Patients Undergoing Outpatient Percutaneous Coronary Intervention: A Report
22 443 from the National Cardiovascular Data Registry's CathPCI Registry. *Circ Cardiovasc*
23 444 *Interv.* 2016;9:e003070.
- 24 445 25. Taggart DP, Altman DG, Gray AM, Lees B, Nugara F, Yu LM, et al. Randomized trial to
25 446 compare bilateral vs. single internal mammary coronary artery bypass grafting: 1-year results of
26 447 the Arterial Revascularisation Trial (ART). *Eur Heart J.* 2010;31:2470-81.
- 27 448 26. Shroyer AL, Hattler B, Wagner TH, Collins JF, Baltz JH, Quin JA, et al. Five-Year Outcomes
28 449 after On-Pump and Off-Pump Coronary-Artery Bypass. *N Engl J Med.* 2017;377:623-632.
- 29 450 27. Brieger DB, Ng ACC, Chow V, D'Souza M, HyunK, Bannon PG, et al. Falling hospital and
30 451 postdischarge mortality following CABG in New South Wales from 2000 to 2013. *Open*
31 452 *Heart.* 2019;6:e000959.
- 32 453 28. Tran DT, Barake W, Galbraith D, Norris C, Knudtson ML, Kaul Pet al. Total and Cause-
33 454 Specific Mortality After Percutaneous Coronary Intervention: Observations From the Alberta
34 455 Provincial Project for Outcome Assessment in Coronary Heart Disease Registry. *CJC Open.*
35 456 2019;1:182-189.
- 36 457 29. Spoon DB, Psaltis PJ, Singh M, Holmes DR Jr, Gersh BJ, Rihal CS, et al. Trends in cause of
37 458 death after percutaneous coronary intervention. *Circulation.* 2014;129:1286-94.
- 38 459 30. Gutacker N, Bloor K, Cookson R, Gale CP, Maynard A, Pagano D, et al. Hospital Surgical
39 460 Volumes and Mortality after Coronary Artery Bypass Grafting: Using International
40 461 Comparisons to Determine a Safe Threshold. *Health Serv Res.* 2017;52:863-878.
- 41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

°	CABG					PCI					TOTAL		
	1998-2002	2003-2007	2008-2012	2013-2017	p _(TL)	1998-2002	2003-2007	2008-2012	2013-2017	p _(TL)	CABG	PCI	p
n(%) ^a	27141(31)	24521(16.7)	21584(11.7)	20436(11)	<0.001	60440(69)	122310(83.3)	162846(88.3)	164698(89)	<0.001	93682(15.5)	5102294(84.5)	<0.001
Age(years)	64.9±9.5	66±9.7	66.1±10	66.3±9.7	<0.001	64±11	65.9±11.1	67±11.5	67.6±11.6	<0.001	65.8±9.7	66.6±11.5	<0.001
Age(ranges)					<0.001*					<0.001*			
≤60	7634(28.1)	6498(26.5)	5797(26.8)	5360(26.2)	<0.001	20883(34.6)	36802(30.1)	45210(27.8)	44779(27.2)	<0.001	25285(27)	147674(28.9)	<0.001
60-70	10292(37.9)	8073(32.9)	7209(33.4)	7230(35.4)	<0.001	19442(32.2)	34783(28.4)	451752(27.7)	45878(27.9)	<0.001	32805(35)	145275(28.5)	<0.001
70-80	8684(32)	9077(37)	7436(34.4)	6579(32.2)	<0.001	17406(28.8)	40393(33)	51357(31.5)	46378(28.8)	<0.001	31776(33.9)	156540(30.7)	<0.001
>80	531(2)	873(3.6)	1147(5.3)	1267(6.2)	<0.001	2711(4.5)	10338(8.5)	21096(13)	26647(16.2)	<0.001	3818(4.1)	60794(11.9)	<0.001
Female sex	5379(19.8)	4768(19.5)	3776(17.5)	3353(16.4)	<0.001	13191(21.8)	29700(24.3)	39773(24.4)	39387(23.9)	<0.001	17276(18.4)	122046(23.9)	<0.001
High blood pressure	12264(45.2)	14540(59.3)	14166(65.6)	13896(68)	<0.001	26005(43)	68897(56.3)	100802(61.8)	103762(63.1)	<0.001	54866(58.6)	299466(58.7)	0.05
Previous MI ^b	3471(12.8)	3944(16.1)	3328 (15.4)	4132 (20.2)	<0.001	11383(18.8)	29608(24.2)	4669 (28.7)	58465(35.5)	<0.001	14875 (15.9)	146150(28.6)	<0.001
NSTEACS	8189(30.2)	6085(24.8)	4538(21)	4236(20.7)	<0.001	25495(42.2)	44821(36.6)	53322(32.7)	54260(33)	<0.001	23048(24.6)	177898(34.9)	<0.001
CHF ^b	1498(5.5)	1737(7.1)	2101(9.7)	2111(10.3)	<0.001	2745(4.5)	9475(7.8)	17662(10.9)	21218(12.9)	<0.001	7447(8)	51100(10)	<0.001
PVD ^b	1750(6.5)	2240(9.1)	2238(10.4)	2182(10.7)	<0.001	4431(7.3)	10380(8.5)	12581(7.7)	12754(7.7)	<0.001	8410(9)	40146(7.7)	<0.001
CVD^b	745(2.7)	1122(4.6)	1221(5.7)	1361(6.7)	<0.001	897(1.5)	2566(2.1)	4410(2.7)	4911(3)	<0.001	4449(4.8)	12784(2.5)	<0.001
Diabetes ^b	7493(27.6)	8799(35.9)	8509(39.4)	8804 (43.1)	<0.001	13131(21.7)	37880(31)	55245(33.9)	57511(34.9)	<0.001	33605(35.9)	163767(32.1)	<0.001
CKD ^b	423(1.6)	701(2.9)	1441(6.7)	1952(9.6)	<0.001	1066(1.8)	3689(3)	12165(7.5)	16094(9.8)	<0.001	4517(4.8)	33014(6.5)	<0.001
COPD ^b	959(3.5)	1396(5.7)	1322(6.1)	1518(7.4)	<0.001	2241(3.7)	6276(5.1)	10268(6.3)	12677(7.7)	<0.001	5195(5.6)	31462(6.2)	<0.001
Liver failure ^b	241(0.9)	331(1.4)	410(1.9)	560(2.7)	<0.001	460(0.8)	1392(1.1)	2497(1.5)	3496(2.2)	<0.001	1541(1.6)	8046(1.6)	0.11
Charlson's Index	2.7(1.4)	3.1(1.5)	3.3(1.7)	3.5(1.8)	<0.001	2.6(1.5)	3(1.7)	3.4(1.9)	3.6(2)	<0.001	3.1(1.6)	3.3(1.9)	<0.001
Previous CABG	1101(4.1)	1085(4.4)	146(0.7)	146(0.7)	<0.001	1727(2.9)	3374(2.8)	4359(2.7)	5417(3.3)	<0.001	2475(2.6)	14877(2.9)	<0.001
Previous PCI	1573(5.8)	1990(8.1)	2704(12.5)	3204(15.7)	<0.001	8163(13.5)	23004(18.8)	40898(25.1)	47890(29.1)	<0.001	9470(10.1)	119955(23.5)	<0.001
Hospital without CABG on site						10151(17.4)	36425(30.7)	64882 (40.9)	65260(40.9)	<0.001		173718(35.7)	
Revascularization 3+ vessels	11326 (41.7)	9206(37.5)	7947(36.8)	7357(36)	<0.001	-	-	11312(7)	11792(7.2)	<0.001	32849(40.5)	23106/327528 (7.1)	<0.001
Outpatient PCI						-	1371(1.1)	7200(4.4)	6358(3.9)	<0.001		14933/449843 (3.3)	
BMS						60107(99.5)	91516(74.8)	67018 (41.2)	34090 (20.7)	<0.001		252731(49.5)	
DES							34873(28.5)	89198(54.8)	115643(70.2)	<0.001		239714/449843(53.3)	
IVUS							1037(0.9)	6104(3.8)	4517(2.7)	<0.001		11658/449843 (2.6)	
ITA	19643(72.3)	21635(88.2)	19646(90.9)	19928(96.9)	<0.001	-	-	-	-	-	80852(86.1)	-	-
Bilateral ITA	2168(8)	3218(13.1)	3454(16)	4816(23.6)	<0.001	-	-	-	-	-	13654(14.6)	-	-
Off Pump CABG	8496(31.3)	8708(35.5)	7178(33.3)	6984(34.2)	<0.001	-	-	-	-	-	31365(33.5)	-	-
Hospital Volume					<0.001*					<0.001*			<0.001
Low	3868(15.1)	3053(12.6)	2404(11.2)	2080(10.2)	<0.001	3259(5.6)	6004(5.1)	7612(4.8)	8002(5)	<0.001	11405(12.4)	24877(5)	<0.001
Low- Interm	5511(21.5)	4671(19.3)	4272(19.9)	3901(19.1)	<0.001	8150(14)	17226(14.5)	21447(13.5)	23155(14.2)	<0.001	18255(20)	69988(14.1)	<0.001
Interm- High	7149(27.8)	6984(28.8)	6446(30)	5693(27.9)	<0.001	15949(27.4)	33545(28.3)	45083(28.5)	47527 (29.7)	<0.001	26272(28.6)	142104(28.7)	0.128
High	9156(35.7)	9524(39.3)	8377(39)	8708(42.7)	<0.001	30870(53)	61902(52.2)	84335(53.2)	80730(51)	<0.001	35765(40)	257837(52.1)	<0.001

Table 1. Baseline and procedural characteristics of PCI (percutaneous coronary intervention) or CABG (Coronary artery bypass grafting). Data is expressed with n(%) or mean SD. p_(TL) contrast test for linear trend. *No contrast for linear trend. a. Number of CABG or PCI divided by the volume of revascularizations. b. according to Charlson's index definition(16,17). MI: Myocardial infarction. CHF: Congestive heart failure. PVD: peripheral vascular disease. CKD: Chronic kidney disease. CVD: Cerebrovascular disease. COPD: Chronic obstructive pulmonary disease. BMS: bare metal stent, DES: drug eluting stent ITA: internal thoracic artery.

CABG			PCI		
Variable	OR CI 95%	p	Variable	OR CI 95%	p
Region of Spain	Not Shown	<0.001	Region of Spain	Not Shown	<0.001
Hospital Volume of CABG (as compared to Low Volume centres)			Hospital Volume of PCI (as compared to Low Volume centres)		
Low-Intermediate	0.86(0.77;0.95)	0.004	Low-Intermediate	1.4(1.18;1.68)	<0.001
Intermediate-High	0.81(0.73;0.9)	<0.001	Intermediate-High	2.05(1.67;2.36)	<0.001
High	0.77(0.68;0.86)	<0.001	High	2.05(1.73;2.42)	<0.001
COPD	1.35(1.2;1.53)	<0.001	COPD	1.25(1.15;1.35)	<0.001
Age (as compared to <60)			Age (as compared to <60)		
60-70	1.72(1.55;1.91)	<0.001	60-70	1.69(1.54;1.85)	<0.001
70-80	3.02(2.73;3.33)	<0.001	70-80	2.6(3.38;2.84)	<0.001
>80	5.07(4.38;5.88)	<0.001	>80	3.58(3.26;3.93)	<0.001
Female sex	1.14(1.06;1.23)	0.001	Female sex	1.09(1.03;1.15)	0.004
Previous MI	2.81(2.62;3.01)	<0.001	Previous MI	2.62(2.49;2.76)	<0.001
NSTE ACS as primary diagnosis	1.2(1.12;1.28)	<0.001			
CHF	3.21(2.96;3.49)	<.001	CHF	4.63(4.39;4.9)	<0.001
PVD	1.43(1.29;1.57)	<.001	PVD	1.24(1.15;1.34)	<0.001
CVD	1.72(1.52;1.94)	<.001	CVD	2.29(2.08;2.52)	<0.001
CKD	1.75(1.55;1.99)	<.001	CKD	1.56(1.45;1.67)	<0.001
On pump CABG	1.09(1.02;1.17)	0.017			
Bilateral ITA	0.8 (0.71; 0.89)	0.042			
Period of study (as compared to 1997-2002)			Period of study (as compared to 1997-2002)		
2003-2007	0.66(0.61;0.72)	<0.001	2003-2007	1.09(0.99;1.21)	0.09
2008-2012	0.41(0.38;0.46)	<0.001	2008-2012	1.18(1.06;1.31)	0.002
2013-2017	0.29(0.26;0.32)	<0.001	2013-2017	1.18(1.06;1.32)	0.002
			Hospital without CABG on site	0.86(0.8;0.92)	<.001
			Diabetes	1.58(1.45;1.67)	<.001
			BMS	0.86(0.79;0.94)	<0.001
			DES	0.41(0.38;0.45)	0.001

Table 2. Factors associated to in-hospital mortality. CABG: coronary artery bypass grafting. PCI: percutaneous coronary intervention. COPD: chronic obstructive pulmonary disease. MI: myocardial infarction. NSTEMI: non-ST elevation acute coronary syndrome. PVD: peripheral vascular disease. CHF: congestive heart failure. CVD: cerebrovascular disease. CKD: chronic kidney disease. ITA: Internal thoracic artery. BMS: Bare meta stent. DES: Drug eluting stent.

1
2
3 Figure 1. Flow diagram. Selection of episodes.
4

5 Figure 2. Number of procedures per million inhabitants and year. A) Volume of procedures per
6 year. Number of total revascularizations and CABG are shown. B) number of procedures by sex
7 and million inhabitants. The number of procedures of each type is represented by sex and million
8 inhabitants of each sex throughout the study period.
9

10 Figure 3. Number of procedures per million inhabitants and year in age ranges. A: PCI B: CABG
11
12

13 Figure 4. Non adjusted and adjusted in-hospital mortality. RAMR: Risk adjusted mortality rate.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Flow diagram. Selection of episodes.

83x134mm (300 x 300 DPI)




Figure 2. Number of procedures per million inhabitants and year. A) Volume of procedures per year. Number of total revascularizations and CABG are shown. B) number of procedures by sex and million inhabitants. The number of procedures of each type is represented by sex and million inhabitants of each sex throughout the study period.

83x116mm (300 x 300 DPI)




Figure 3. Number of procedures per million inhabitants and year in age ranges. A: PCI B: CABG

83x110mm (300 x 300 DPI)




Figure 4. Non adjusted and adjusted in-hospital mortality. RAMR: Risk adjusted mortality rate.

83x111mm (300 x 300 DPI)

Supplementary Material

Table 1. ICD9 and ICD10 codes

	ICD9	ICD10
CABG	36.1x	0210xxx,0211xxx,0212xxx,0213xxx
PCI	00.66, 36.03, 36.06, 36.07, 36.09	0270xxx, 0271xxx,0272xxx,0273xxx, 02C0xxx, 02C1xxx, 02C2xxx, 02C3xxx, 02C4xxx
Excluded Concomitant procedures	35.xx, 37.3x, 37.51, 38.44, 38.45, 39.1x, 39.2x, 39.3x & 37.90	027Fxxx, 027Gxxx, 02NFxxx, 02NGxxx, 02Vxxxx, 027Jxxx, 02NJxxx, 02Nxxxx, 02Rxxxx, 02Qxxxx, 028xxxx, 02Bxxxx, 02Cxxxx (different from 02C0xxx, 02C1xxx, 02C3xxx and 02C4xxx), 02Fxxxx, 02Hxxxx, 02Jxxxx, 02Kxxxx, 02Nxxxx, 02Pxxxx, 02Uxxxx, 02Wxxxx, 02Yxxxx, 025xxxx
STEMI	410.x1	I21.x9, I21.x1, I21.x, I21.4, I21.3, I21.9

CABG: coronary artery bypass grafting. PCI: percutaneous coronary intervention. AMI: acute myocardial infarction STEMI: ST elevation myocardial infarction

Table 2. Excluded volume and main reasons for exclusion throughout the study period.

	1997-2002	2003-2007	2008-2012	2013-2017	Total	p _{LT}
N	123593	229843	304095	320266	977797	
Acute STEMI	24316 (19.7)	60527 (26.3)	89136 (29.3)	99969 (31.2)	273948 (28)	<0.001
Coding *	7048 (5.7)	16264 (7.1)	28490 (9.4)	36700 (11.5)	88502 (9.1)	<0.001
Concomitant procedures	6319 (5.1)	11559 (5)	12603 (4.1)	15173 (4.7)	45654 (4.7)	<0.001
PCI & CABG in the same episode	447 (0.4)	580 (0.3)	777 (0.3)	781 (0.2)	2585 (0.3)	<0.001
Age <18 or >100	179 (0.1)	193 (0.1)	236 (0.1)	175 (0.1)	783 (0.1)	<0.001
Exclusion	36012 (29.1)	83012 (36.1)	119665 (39.4)	135132 (42.2)	373821 (38.2)	<0.001

PCI: Percutaneous coronary intervention. CABG: Coronary artery bypass grafting. LT: Linear trend. * Including coding errors, consolidated episodes, staged procedures..

Figure 1. Changes in the volume of excluded episodes.




Figure 2. Absolute number of procedures per year.






Figure 3. Absolute number of procedures depending on coronary syndrome.



It is observed that the proportion of CABG performed in patients with NSTEMI remained stable throughout the study period. However, there was a more marked increase in the number of PCI procedures in patients without NSTEMI. NSTEMI: non-ST elevation acute coronary syndrome.

Figure 4. Mean Charlson's Index.



	CABG					PCI					TOTAL		
	1998-2002	2003-2007	2008-2012	2013-2017	p _(TL)	1998-2002	2003-2007	2008-2012	2013-2017	p _(TL)	CABG	PCI	p
n(%) ^a	7494 (36.3)	8799 (18.9)	8509 (13.4)	8805 (13.3)	<0.001	13131 (63.7)	37878 (81.2)	55246 (86.7)	57518 (86.7)	<0.001	33607 (17)	163773 (83)	<0.001
Revascularization 3+ vessels	2118(32.7)	2182(28.4)	2043(27.4)	1835(22.9)	<0.001	-	-	4853 (8.9)	4876 (8.5)	<0.001	8178 (27.6)	9729/112764 (8.6)	<0.001
Number of stents													
<3								44791 (81.1)	51306 (91.2)	<0.001		96097/112764 (85.2)	<0.001
≥3								10455 (18.9)	6212 (10.8)	<0.001		16667/112764(14.8)	<0.001
BMS						60440 (99.5)	91514 (74.8)	67011 (41.2)	34085 (20.7)	<0.001		252715(20.7)	<0.001
DES							34868 (28.5)	89196 (54.8)	115652 (70.2)	<0.001		239716 (47)	<0.001
Bilateral ITA	519 (6.9)	1037 (11.8)	1175 (13.8)	1844 (20.9)	<0.001	-	-	-	-	-	4575 (13.6)	-	-
Off Pump CABG	8496(31.3)	8708(35.5)	7178(33.3)	6984(34.2)	<0.001	-	-	-	-	-	31365(33.5)	-	-

Table 3. Procedural characteristics of PCI (percutaneous coronary intervention) or CABG (Coronary artery bypass grafting) among patients with diabetes. Data is expressed with n(%). p_(TL) contrast test for linear trend. *No contrast for linear trend. a. Number of CABG or PCI divided by the volume of revascularizations in diabetic patients. BMS: bare metal stent, DES: drug eluting stent ITA: internal thoracic artery.

Table 4. Variables included in the model to detect factor associated to in-hospital mortality after CABG and PCI.

	Model to detect factors associated for in hospital mortality after CABG	Model to detect factors associated for in hospital mortality after PCI
Variables	Spanish region, Groups of hospitals according to the volume of CABG/year-center, COPD, Age ranges, Sex, Previous MI, NSTEMI on admission, PVD, CVD, Diabetes, CKD, Previous CABG, Previous PCI, Off-Pump, CHF, bilateral ITA, Period of study	CABG on site, Spanish region, Groups of hospitals according to the volume of PCI/year-center, COPD, Age ranges, Sex, Previous MI, NSTEMI on admission, PVD, CVD, Diabetes, CKD, Previous CABG, Previous PCI, BMS, DES, CHF, Period of study
AUC	0.76 (95%CI 0.76;0.77)	0.81 (95%CI 0.81;0.82)


CABG: coronary artery bypass grafting. PCI: percutaneous coronary intervention. COPD: chronic obstructive pulmonary disease. MI: myocardial infarction. NSTEMI: non-ST elevation acute coronary syndrome. PVD: peripheral vascular disease. CHF: congestive heart failure. CVD: cerebrovascular disease. CKD: chronic kidney disease. ITA: Internal thoracic artery. BMS: implantation of bare metal stent. DES: Implantation of drug eluting stent. AUC Area Under the Curve.

Table 5. Variables included in the model to estimate expected in-hospital mortality after CABG and PCI.

	Model to detect factors associated for in hospital mortality after CABG	Model to detect factors associated for in hospital mortality after PCI
Variables	Spanish region, Groups of hospitals according to the volume of CABG/year-center, COPD, Age ranges, Sex, Previous MI, NSTEMI on admission, PVD, CVD, Diabetes, CKD, Previous CABG, Previous PCI, Off-Pump, CHF, bilateral ITA, High blood pressure	CABG on site, Spanish region, Groups of hospitals according to the volume of PCI/year-center, COPD, Age ranges, Sex, Previous MI, NSTEMI on admission, PVD, CVD, Diabetes, CKD, Previous CABG, Previous PCI, BMS, DES, CHF, high blood pressure.
AUC	0.74 (95%CI 0.73;0.75)	0.81 (95%CI 0.81;0.82)

CABG: coronary artery bypass grafting. PCI: percutaneous coronary intervention. COPD: chronic obstructive pulmonary disease. MI: myocardial infarction. NSTEMI: non-ST elevation acute coronary syndrome. PVD: peripheral vascular disease. CHF: congestive heart failure. CVD: cerebrovascular disease. CKD: chronic kidney disease. ITA: Internal thoracic artery. BMS: implantation of bare metal stent. DES: Implantation of drug eluting stent. AUC Area Under the Curve.

Figure 5. Median Number of Procedures/Hospital- year and Number of Hospitals reporting data to MBDS.



Left axis: median procedures/hospital. Right axis: number of hospitals reporting data to MBDS

Table 6. Number of hospitals and volume of procedures/hospital in each study period

	1998-2002	2003-2007	2008-2012	2013-2017	p(LT)
Median number of hospitals/year					
(+)CABG(+)PCI	37(36;40)	44(42;44)	47(47;47)	48(45;50)	<0.001
(-)CABG(+)PCI	25(19;32)	61(54;62)	93(88;95)	96(77;99)	<0.001
Median number of procedures/center-year					
CABG	130.5(102;163)	103(73;145)	89(58;120)	75.5(50.5;114)	<0.001
PCI	148(58;249)	195(77;334)	186(71;340)	198(80.5;350.5)	<0.001
Mortality according to hospital volume of procedures					
Hospital Volume of CABG					
Low Volume	330/3866(8.5)	206/3053(6.8)	87/2406(3.6)	74/2079(3.6)	<0.001
Low-Intermediate	411/5511(7.5)	322/4671(6.9)	170/4272(4)	108/3901(2.8)	<0.001
Low-High	530/7149(7.4)	345/6984(4.9)	226/6446(3.5)	172/5694(3)	<0.001
High	469/9156(5.1)	352/9524(3.7)	265/8376(3.2)	222/8708(2.6)	<0.001
Hospital Volume of PCI					
Low Volume	18/3259(0.6)	31/6004(0.5)	45/7613(0.6)	65/8052(0.8)	0.04
Low-Intermediate	67/8160(0.8)	155/17226(0.9)	204/21446(1)	264/23081(1.1)	0.003
Low-High	172/15950(1.1)	426/33545(1.3)	682/45088(1.5)	758/47881(1.6)	<0.001
High	296/30869(1)	745/61896(1.2)	1225/84334(1.5)	1140/80415(1.4)	<0.001

Table 3. Data are shown as n(%) or median and IQR. CABG: "Coronary Artery Bypass Grafting". PCI: "Percutaneous Coronary Intervention. (+)CABG(+)PCI: Hospitals with CABG and PCI: (-)CABG(+)PCI. Hospitals without CABG but with PCI.

The RECORD statement – checklist of items, extended from the STROBE statement, that should be reported in observational studies using routinely collected health data.

	Item No.	STROBE items	Location in manuscript where items are reported	RECORD items	Location in manuscript where items are reported
Title and abstract					
	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found	Title	RECORD 1.1: The type of data used should be specified in the title or abstract. When possible, the name of the databases used should be included. RECORD 1.2: If applicable, the geographic region and timeframe within which the study took place should be reported in the title or abstract. RECORD 1.3: If linkage between databases was conducted for the study, this should be clearly stated in the title or abstract.	Article Summary Title Article Summary NA
Introduction					
Background rationale	2	Explain the scientific background and rationale for the investigation being reported	Introduction		
Objectives	3	State specific objectives, including any prespecified hypotheses	Introduction		
Methods					
Study Design	4	Present key elements of study design early in the paper	Article Summary		
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Materials and Methods		

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27	Participants	6	<p>(a) <i>Cohort study</i> - Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up</p> <p><i>Case-control study</i> - Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls</p> <p><i>Cross-sectional study</i> - Give the eligibility criteria, and the sources and methods of selection of participants</p> <p>(b) <i>Cohort study</i> - For matched studies, give matching criteria and number of exposed and unexposed</p> <p><i>Case-control study</i> - For matched studies, give matching criteria and the number of controls per case</p>	Materials and Methods	<p>RECORD 6.1: The methods of study population selection (such as codes or algorithms used to identify subjects) should be listed in detail. If this is not possible, an explanation should be provided.</p> <p>RECORD 6.2: Any validation studies of the codes or algorithms used to select the population should be referenced. If validation was conducted for this study and not published elsewhere, detailed methods and results should be provided.</p> <p>RECORD 6.3: If the study involved linkage of databases, consider use of a flow diagram or other graphical display to demonstrate the data linkage process, including the number of individuals with linked data at each stage.</p>	Materials and Methods and Supplemental material NA NA
28 29 30 31 32 33 34	Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable.	Materials and Methods and Supplemental Material	RECORD 7.1: A complete list of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be provided. If these cannot be reported, an explanation should be provided.	Materials and Methods and supplemental material
35 36 37 38 39 40 41 42	Data sources/ measurement	8	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Materials and Methods and Supplemental Material		

43
44
45
46
47

1 2 3	Bias	9	Describe any efforts to address potential sources of bias	Materials and Methods (Statistical Analysis)		
4 5	Study size	10	Explain how the study size was arrived at	Materials and Methods & Figure 1		
6 7 8 9 10 11	Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen, and why	Materials and Methods		
12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35	Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) <i>Cohort study</i> - If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> - If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> - If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses	Materials and Methods (Statistical Analysis)		
36 37 38 39 40 41 42 43 44	Data access and cleaning methods		..	Materials and Methods	RECORD 12.1: Authors should describe the extent to which the investigators had access to the database population used to create the study population.	Materials and Methods and Introduction

				RECORD 12.2: Authors should provide information on the data cleaning methods used in the study.	Materials and Methods. Figure 1.
Linkage		..	NA	RECORD 12.3: State whether the study included person-level, institutional-level, or other data linkage across two or more databases. The methods of linkage and methods of linkage quality evaluation should be provided.	
Results					
Participants	13	(a) Report the numbers of individuals at each stage of the study (<i>e.g.</i> , numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed) (b) Give reasons for non-participation at each stage. (c) Consider use of a flow diagram	Results. Section: 2 <i>Study Population</i> “. Figure 1.	RECORD 13.1: Describe in detail the selection of the persons included in the study (<i>i.e.</i> , study population selection) including filtering based on data quality, data availability and linkage. The selection of included persons can be described in the text and/or by means of the study flow diagram.	Results. Section: 2 <i>Study Population</i> “. Figure 1.
Descriptive data	14	(a) Give characteristics of study participants (<i>e.g.</i> , demographic, clinical, social) and information on exposures and potential confounders (b) Indicate the number of participants with missing data for each variable of interest (c) <i>Cohort study</i> - summarise follow-up time (<i>e.g.</i> , average and total amount)	Results. Section: “ <i>Study Population</i> ” Table 1. Supplemental material.		
Outcome data	15	<i>Cohort study</i> - Report numbers of outcome events or summary measures over time <i>Case-control study</i> - Report numbers in each exposure	Results. Section “Mortality”		

		category, or summary measures of exposure <i>Cross-sectional study</i> - Report numbers of outcome events or summary measures			
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Results. Table 2. Section: “Mortality”		
Other analyses	17	Report other analyses done— e.g., analyses of subgroups and interactions, and sensitivity analyses	NA		
Discussion					
Key results	18	Summarise key results with reference to study objectives	Discussion. Par 1.		
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Discussion. Par 1 “Limitations” section	RECORD 19.1: Discuss the implications of using data that were not created or collected to answer the specific research question(s). Include discussion of misclassification bias, unmeasured confounding, missing data, and changing eligibility over time, as they pertain to the study being reported.	Discussion. Par 1 “Limitations” section
Interpretation	20	Give a cautious overall interpretation of results considering objectives,	Discussion. Par 1 “Conclusion” section		

		limitations, multiplicity of analyses, results from similar studies, and other relevant evidence			
Generalisability	21	Discuss the generalisability (external validity) of the study results	NA		
Other Information					
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Footnotes		
Accessibility of protocol, raw data, and programming code		..	Footnotes	RECORD 22.1: Authors should provide information on how to access any supplemental information such as the study protocol, raw data, or programming code.	Footnotes

*Reference: Benchimol EI, Smeeth L, Guttman A, Harron K, Moher D, Petersen I, Sørensen HT, von Elm E, Langan SM, the RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. *PLoS Medicine* 2015; in press.

*Checklist is protected under Creative Commons Attribution ([CC BY](https://creativecommons.org/licenses/by/4.0/)) license.

BMJ Open

Retrospective cohort analysis of Spanish national trends of coronary artery bypass grafting and percutaneous coronary intervention from 1998 to 2017

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-046141.R2
Article Type:	Original research
Date Submitted by the Author:	18-Feb-2021
Complete List of Authors:	CARNERO ALCAZAR, MANUEL; Hospital Clínico Universitario San Carlos Instituto Cardiovascular, Cardiac Surgery Hernandez-Vaquero, Daniel ; Hospital Universitario Central de Asturias, Cardiac Surgery Cubero-Gallego, Hector; Hospital del Mar, Cardiology. Unit of Interventional Cardiology. Lopez Menendez, Jose; Hospital Ramon y Cajal, Cardiac Surgery Piñon, Miguel; Alvaro Cunqueiro Hospital, Cardiac Surgery Albors Martin, Jose; Hospital Universitario del Vinalopó, Cardiac Surgery Cuerpo Caballero, Gregorio; Hospital General Universitario Gregorio Marañón, Cardiac Surgery Cobiella Carnicer, Javier; Hospital Clínico Universitario San Carlos Instituto Cardiovascular, Cardiac Surgery Villamor, Cristina; Hospital Clinico Universitario San Carlos, Internal Medicine Forteza, Alberto; Puerta del Hierro University Hospital of Majadahonda, Cardiac Surgery Pascual, Isaac; Hospital Universitario Central de Asturias, Cardiology. Unit of Interventional Cardiology. Maroto Castellanos, Luis; Hospital Clínico Universitario San Carlos Instituto Cardiovascular, Cardiac Surgery
Primary Subject Heading:	Cardiovascular medicine
Secondary Subject Heading:	Epidemiology, Public health
Keywords:	Coronary heart disease < CARDIOLOGY, Cardiac Epidemiology < CARDIOLOGY, PUBLIC HEALTH, Cardiac surgery < SURGERY, Coronary intervention < CARDIOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **1 Title: Retrospective cohort analysis of Spanish national trends of coronary artery bypass**
4 **2 grafting and percutaneous coronary intervention from 1998 to 2017.**

5 3
6 4 **Authors:**

7 5
8 6 Manuel Carnero-Alcázar(1), Daniel Hernandez-Vaquero(2), Héctor Cubero-Gallego (3), José
9 7 López-Menéndez(4), Miguel Piñón(5), José Albors-Martín(6), Gregorio Cuerpo-Caballero(7),
10 8 Javier Cobiella-Carnicer(1), Cristina Villamor (8), Alberto Forteza (9), Isaac Pascual (10),
11 9 Luis C Maroto-Castellanos(1)

12 10
13 11 1.Department of Cardiac Surgery. Hospital Clínico San Carlos. CardioRed1. Madrid. Spain.
14 12 2.Department of Cardiac Surgery. Hospital Central de Asturias. Oviedo. Spain.
15 13 3.Unit of Interventional Cardiology. Department of Cardiology. Hospital del Mar. Barcelona,
16 14 Spain.
17 15 4. Department of Cardiac Surgery. Hospital Ramón y Cajal. Madrid. Spain.
18 16 5. Department of Cardiac Surgery. Hospital Álvaro Cunqueiro. Vigo. Spain.
19 17 6. Department of Cardiac Surgery. Hospital del Vinalopó. Alicante. Spain.
20 18 7. Department of Cardiac Surgery. Hospital Gregorio Marañón. Madrid. Spain.
21 19 8. Department of Internal Medicine. Hospital Clínico San Carlos. Madrid. Spain.
22 20 9. Department of Cardiac Surgery. Hospital Puerta de Hierro. Majadahonda. Spain.
23 21 10. Unit of Interventional Cardiology. Department of Cardiology. Hospital Universitario
24 22 Central de Asturias. Oviedo, Spain.
25 23
26 24
27 25

28 26 **Corresponding author:** Manuel Carnero Alcázar. Dpt. of Cardiac Surgery. Hospital Clínico
29 27 San Carlos. Plaza Cristo Rey s/n.28040. Madrid. Spain. Email: E-mail:
30 28 mcarneroalcazar@gmail.com Tlph: +34646773287
31 29

32 30
33 31 **Structured abstract & article summary: 358**

34 32 **Abstract: 270**

35 33 **Text: 3395**

36 34 **References: 971**

37 35 **Tables and Figures: 922**
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

36 Article Summary

38 Abstract

40 **Introduction.** Spain is one of the countries with the lowest rates of revascularization and highest
41 ratio of percutaneous coronary intervention (PCI) to coronary artery bypass grafting (CABG).

42 **Objectives.** To investigate the changes and trends in the two revascularization procedures
43 between 1998 and 2017 in our country.

44 **Design.** Retrospective cohort study. Analysis of in-hospital outcomes.

45 **Setting.** Minimum Basic Dataset from the Spanish National Department of Health: mandatory
46 database collecting information of patients who are attended in the Spanish public National Health
47 System.

48 **Participants.** 603,976 patients who underwent isolated CABG or PCI in the Spanish National
49 Health System. The study period was divided in four 5-year intervals. Patients with acute
50 myocardial infarction on admission were excluded.

51 **Primary and Secondary Outcomes:** We investigated the volume of procedures nationwide, the
52 changes of the risk profile of patients and in-hospital mortality of both techniques.

53 **Results.** We observed a 2.2-fold increase in the rate of any type of myocardial
54 revascularization/million inhabitants-year: 357(1998) to 776(2017). 93,682(15.5%) had a
55 coronary surgery. PCI to CABG ratio rose from 2.2 (1998-2002) to 8.1 (2013-2017). Charlson's
56 index increased by 0.8 for CABG and 1 for PCI. The median annual volume of PCI/hospital
57 augmented from 136 to 232, while the volume of CABG was reduced from 137 to 74. In the two
58 decades, we detected a significant reduction of CABG in-hospital mortality (6.5% Vs
59 2.6%, $p<0.001$) and a small increase in PCI (1.2% Vs 1.5%, $p<0.001$). Risk adjusted mortality rate
60 was reduced for both CABG (1.51 Vs 0.48, $p<0.001$), and PCI (1.42 Vs. 1.05, $p<0.001$).

61 **Conclusion.** We detected a significant increase in the volume of revascularizations (particularly
62 PCI) in Spain. Risk-adjusted in-hospital mortality was significantly reduced

64 Strengths and limitations.

- 65 • This is the first study to investigate the nationwide changes and trends in coronary
66 revascularization in Spain during the past two decades.
- 67 • It was based on a very large and detailed administrative database which included most of
68 the episodes of patients who have been admitted to any public NHS hospital between 1998-2017.
- 69 • Follow up information is not available
- 70 • The analysis might be biased by administrative information coding errors and missings.
- 71 • However, no other source of information allows to perform a long-term nationwide
72 investigation like this.

INTRODUCTION

Surgical and percutaneous myocardial revascularization have demonstrated to improve symptoms and life expectancy in patients with advanced coronary artery disease. In the vast majority of patients with ST-elevation acute coronary syndrome, percutaneous coronary intervention (PCI) is the preferred strategy(1). However, in chronic stable angina or non-ST elevation acute coronary syndromes, the choice between PCI and coronary artery bypass grafting (CABG) depends on multiple factors. In this scenario, the best therapeutic option for each patient must be decided(1,2) by a multidisciplinary “Heart Team”.

Many authors have investigated large national registries and analyzed the changes of both techniques over time and the distribution of CABG and PCI across different regions and countries (3-6). Spain is, according to the OECD(6), one of the European countries with the lowest rates of revascularization and the one with the highest ratio of PCI to CABG. The causes of the magnitude of this disbalance have never been studied in depth. Moreover, there is no robust evidence on the evolution of the two techniques in terms of their results and variability, nor the risk profile of CABG and PCI patients in the Spanish National Health System (NHS).

In our country, there are no patient-level clinical registries specifically dedicated to patients with coronary artery disease undergoing myocardial revascularization. The Spanish Society of Thoracic and Cardiovascular Surgery and the Spanish Society of Cardiology annually report the national volumes and outcomes of CABG and PCI (7,8). However, these reports are based on voluntary, aggregated and unaudited information submitted by hospitals. On the other hand, the healthcare centers of the Spanish NHS have to report the administrative information of all admitted patients to a mandatory nationwide registry: The Minimum Basic Dataset (MBDS) from the Department of Health. The MBDS is a public open access database which stores individual and anonymized data from all discharge reports from all the NHS episodes, coded according to the International Classification of Diseases (ICD). Despite the fact that the use of non-specific administrative sources, such as this one, for the analysis of clinical indicators in the field of cardiology is controversial(9), different studies based on the MBDS have validated its usefulness to analyze the results of clinical processes in Spain(10-14)

We set out to study the evolution of CABG and PCI in Spain between 1998 and 2017 with the information obtained from the MBDS of the Department of Health of our country. Specifically, we analyzed the volume of CABG and PCI, the changes in the risk profile of patients and hospital mortality in the two revascularization strategies. It was not the objective of this study to compare the results of both techniques, taking into account that they have different indications and that follow-up information is not available.

MATERIALS AND METHODS

Sources of information and patient selection

Data was obtained from the MBDS from the Department of Health of Spain. This research was carried out according to the STROBE (Strengthening the Reporting of OBServational studies in Epidemiology) recommendations. This study was approved by the Institutional Review Board and Ethics Committee at Hospital Clínico San Carlos (Madrid,Spain).

The patient selection algorithm can be seen in Figure 1. We investigated all the outpatient or hospitalization episodes of the Spanish NHS from 1998 to 2017 in which a CABG or PCI procedure had been carried out. Those episodes during which, patients underwent concomitant procedures were excluded (See supplementary Table 1 ICD9 and ICD10 codes).

Likewise, all episodes with an acute myocardial infarction/acute coronary syndrome with ST segment elevation as the primary diagnosis on admission (See supplementary Table 1) were excluded, as those with both types of revascularization. In addition, to avoid possible coding errors, patients younger than 18 or older than 100-year-old, patients operated on CABG in centers without CABG or who underwent PCI in centers without PCI were also discarded. Patients discharged alive earlier than two days after CABG were also considered as coding errors. The episodes corresponding to patients who were transferred to another center and consecutive

1
2
3 129 planned revascularizations episodes were consolidated into a single episode(14). Each episode
4 130 corresponds to a single patient, but a patient might have more than one episode. Given that we
5 131 analyzed in-hospital outcomes, different consolidated episodes will be considered as different
6 132 patients for the purpose of this study.

7 133 The full period of time (1998-2017) was divided in four 5-year intervals (1998-2002,
8 134 2003-2007, 2008-2012 and 2013-2017).

9 135

10 136 *Patient and Public Involvement*

11 137

12 138 No patient was actively involved in the study. Information regarding the delivered
13 139 healthcare to the patients included in this investigation was obtained deidentified from the Spanish
14 140 Department of Health

15 141

16 142 *National volume of revascularization procedures and risk profile of the patients*

17 143

18 144 We investigated the absolute number of CABG and PCI per year, the number of
19 145 procedures per million of inhabitants and the changes in the PCI/CABG ratio. Further analyses to
20 146 investigate the trends in the indexed volume of each type of procedure were also performed
21 147 according to sex and age. To estimate the nationwide population, data was extracted from the
22 148 National Institute of Statistics(15).

23 149

24 150 Healthcare centers were classified according to the volume of procedures per year. Thus,
25 151 for both CABG and PCI, hospitals were divided into four groups according to the quartile of the
26 152 volume of PCI or CABG interventions that they performed in each year: Low volume (quartile
27 153 1), Low-Intermediate Volume (quartile 2), High-Intermediate Volume (quartile 3) and High
28 154 Volume (quartile 4) .

29 155

30 156 Patients were classified into four groups according to their age ($\leq 60, >60$ & $\leq 70, >70$ &
31 157 ≤ 80 , and >80 -year-old). We analyzed the evolution of the prevalence of various comorbidities
32 158 Age-modified Charlson's Index was calculated (16,17). In addition, the individual components
33 159 of this score (previous history of myocardial infarction, kidney disease, diabetes, ...) and other
34 160 procedural variables were analyzed throughout the study period (see Table 1).

35 161

36 162 *Mortality*

37 163

38 164 We analyzed in hospital non-adjusted and adjusted mortality for PCI and CABG and its
39 165 changes over the study period.

40 166

41 167 *Statistical Analysis.*

42 168

43 169 Categorical variables were represented with absolute and relative frequencies (%) and
44 170 were compared with the chi-squared test. The normality of the quantitative variables was analyzed
45 171 with PP- plots, and they were expressed with mean and standard deviation or median and
46 172 interquartile range. Imputation was not made for missing values. Statistics were estimated using
47 173 available data. Quantitative variables were compared among the periods of the study with an
48 174 analysis of variance or non-parametric comparison of medians. Contrasts were performed to
49 175 investigate the presence of a linear trends (LT). The relative risk reduction (RRR) and odds ratio
50 176 (OR) were used to represent the strength of association between different variables and mortality.

51 177

52 178 We investigated factors associated to mortality for each type of revascularization. For this
53 179 purpose, we created multivariable models including variables with theoretical value and variables
54 180 related to mortality (statistical significance $p < 0.1$) in an univariable analysis. The best models
55 181 were selected based on the value of the Akaike information criterion, R^2 and their area under the
56 182 curve.

57 183

58 184 Subsequently, we estimated 2 new models to predict mortality after PCI and CABG,
59 185 respectively, excluding the time period. We divided the observed mortality in each year for PCI
60 186 and CABG by that expected according to the corresponding model. In this way, we analyzed the
61 187 evolution of risk- adjusted mortality rate (RAMR) over time. (14).

1
2
3 184 Statistical analysis was performed with Stata v 15.0 (StataCorp. 2017. Stata Statistical
4 185 Software:Release 15.College Station,TX: StataCorp LLC.)
5 186

6 187 **RESULTS**

7 188 8 189 *Study Population*

9 190
10 191 Almost one million (977,797) episodes of CABG or PCI were included in the study.
11 192 Thirty eight percent (373,831) were excluded, and 603,967 were considered for the purpose of
12 193 this study (See Figure 1, Supplementary Table 2 and Supplementary Figure 1). Of these,
13 194 93,682(15.5%) had CABG and 5103,294(84.5%) PCI. There was a linear increase ($p_{LT}<0.001$) in
14 195 the PCI/CABG ratio: 1998-2002: 2.2(69% PCI vs. 31% CABG), 2003-2007:5(83.3% PCI Vs.
15 196 16.7% CABG), 2008-2012:7.6 (88.3% PCI Vs. 11.7% CABG), and 2013-2017:8.1(89% PCI Vs.
16 197 11% CABG) (Table 1). In the general sample, an increase in the number of revascularizations
17 198 was observed, mainly due to a higher number of PCI and a drop in CABG. (Figure 2A). We
18 199 observe relevant differences in the volume of procedures by sex. Overall, more PCI and CABG
19 200 were performed in men than in women, but the difference increased more markedly in PCI (Figure
20 201 2B). Regarding the type of procedure by age range, PCI increased in all age ranges, although the
21 202 increase was more pronounced in those over 60 years of age. On the contrary, CABG significantly
22 203 decreased among those over 70 years of age and experienced a slight decrease in the younger
23 204 population strata (Figure 3). Absolute number of procedures and according to type of coronary
24 205 syndrome is shown in supplementary figures 2 and 3.

25 206 The risk profile of patients worsened throughout the study period (table 1). In PCI and
26 207 CABG groups, we observed a higher mean age and a greater prevalence of risk factors such as
27 208 previous myocardial infarction, heart failure, peripheral vascular disease, diabetes or chronic
28 209 obstructive pulmonary disease (COPD). Consequently, Charlson's Index rose up from 2.7 to
29 210 3.5($p_{LT}<0.001$) in CABG and from 2.6 to 3.6 ($p_{LT}<0.001$) in PCI (Table 1 and Supplementary
30 211 Figure 4).

31 212 We detected a significant growth of PCI in centers without CABG: 1998-2002 (17.4%)
32 213 2013-2017 (41.1%) ($p_{LT}<0.001$). The proportion of patients who had three or more coronary
33 214 arteries revascularized was higher in the CABG group (40.5% Vs 7.1%, $p<0.001$). We observed a
34 215 linear increase in the use of bilateral internal thoracic arteries (8% Vs. 23.6 %, $p_{LT}<0.001$), and
35 216 off-pump CABG (31.3% Vs. 34.2% $p_{LT}<0.001$) from the first to the last period. Similarly, an
36 217 increase in drug eluting stents and a decrease of bare metal stents was observed among PCI
37 218 patients ($p_{LT}<0.001$). The number of outpatient percutaneous procedures was small but increased
38 219 in the las two periods (see table 1). The proportion of patients with previous revascularization
39 220 increased linearly throughout the study: (1998-2002: 13.9%;2003-2007: 19.4%; 2008-
40 221 2012:25.3%; 2013-2017:29.4%; $p_{LT}<0.001$). Most of this increase was due to a growth of
41 222 revascularized patients with previous PCI, while the number of patients undergoing CABG or
42 223 PCI with a history of previous surgery decreased or increased minimally, respectively (Table 1
43 224 and Supplementary Figure 5).

44 225 We observed a growth of episodes of patients with diabetes and an increase of
45 226 percutaneous procedures in this subset. Specific information on patients with diabetes can be
46 227 found in Supplementary table 3.
47 228
48 229

49 230 *Mortality*

50 231
51 232 Among patients undergoing CABG, a reduction in non-adjusted in-hospital mortality
52 233 was observed between 1998 and 2017: 6.5% Vs. 2.6% ($p_{LT}<0.001$; RRR -60%, 95%CI -64.8%;
53 234 -55,2%). Mortality among patients undergoing PCI raised slightly from 1.2% to 1.5% ($p_{LT}<0.001$;
54 235 RRR +25%, 95%CI 22.3%;27.6%) (Figure 4A).

55 236 Table 2 shows factors independently associated to in-hospital mortality after CABG or
56 237 PCI. Most of the factors increased mortality regardless of the type of revascularization (COPD,
57 238 age, previous infarction, heart failure, etc....). The effect of some variables changed depending

1
2
3 239 on the type of revascularization such as the hospital volume of procedures and period of study.
4 240 PCI mortality in centers without CABG was lower than in centers with CABG on site (OR
5 241 0.86,95%CI 0.8; 0.92, $p<0.001$) (more information can be found in Supplementary material)

6 242 Information regarding the estimation of RAMR is shown in Supplementary tables 4 and
7 243 5. A decrease in RAMR was detected in both CABG and PCI patients. In the case of coronary
8 244 surgery, the RAMR decreased from 1.51 to 0.48($p_{LT}<0.001$), and in the case of PCI from 1.42 to
9 245 1.05 ($p_{LT}<0.001$) between 1998 and 2017 respectively (see Figure 4B).

10 246
11 247 *Volume of activity and mortality by center*
12 248

13 249 The number of centers with CABG and PCI on site grew from 37 (1998-2002) to 48
14 250 (2013-2017)($p_{LT}<0.001$)(Supplementary Material : Table 6 and Figure 6). The number of centers
15 251 with PCI but without CABG on site increased from 25 (1998) to 96 (2017). We observed a higher
16 252 median volume of PCI per center from 136 to 232($p_{LT}<0.001$) and a decrease in CABG from 137
17 253 to 74 CABG($p_{LT}<0.001$) between 1998 and 2017. (Supplementary material). The volume of
18 254 interventions was independently associated to a lower in-hospital mortality for CABG and a
19 255 higher mortality after PCI (see table 2)

20 256

21 257 **DISCUSSION**

22 258

23 259 Between 1998 and 2017, in Spain, the volume of revascularizations in patients without
24 260 ST elevation myocardial infarction increased to 776/million inhabitants (See Figure 2). However,
25 261 these rates are very low as compared to other countries. For example, in the United States, the
26 262 number of CABG per million inhabitants in 2007-2008 was 1,081/year, while that of PCI was
27 263 3,667/year(18). In Germany, in 2013, the proportion of revascularizations per 100,000 inhabitants
28 264 was three times higher than in Spain(6). Although the differences can be explained by the lower
29 265 prevalence of coronary heart disease in our country, there are other factors that may influence
30 266 such as a greater difficulty in accessing the healthcare system for patients or a less frequent
31 267 indication for revascularization.

32 268 In addition, there was, over the past 20 years, a 27.7% reduction in the volume of CABG
33 269 (5506 in 1998 Vs 3872 in 2017) and a 3.7-fold increase of PCI volume (8735 in 1998 Vs 32272
34 270 in 2017). During such a long period of time, the indications for CABG and PCI have varied,
35 271 mainly in patients with stable 1 or 2-vessel coronary artery disease, with percutaneous
36 272 revascularization being the most frequently indicated nowadays. In patients with left main or
37 273 three-vessel disease, the indication for PCI has also gained strength, although with less intensity.
38 274 These changes have been mainly due to the development of new percutaneous devices and the
39 275 optimization of medical treatment. (1,19). Even so, different studies have consistently continued
40 276 to detect the benefit of CABG in patients with more complex coronary disease (2,20).

41 277 The PCI/CABG ratio in the last period of the study was 8.1. In the 2015 "*Health at a*
42 278 *Glance*" report, the PCI/CABG ratio was 7.3 in Spain, close to that observed in this study and
43 279 more than double the average of the countries included in that report: 3.55(6). Similar changes
44 280 have happened in other countries. For example, the analysis of the US National Inpatient Sample
45 281 registry found a decline in the volume of CABG of 116% between 1998 and 2015(21) and 14%
46 282 between 2001 and 2007 with a stabilization of the volume of PCI(18). The New York State
47 283 registry detected an increase in the PCI/CABG ratio between 1994 and 2008 from 1.12 to 5.14(5).
48 284 The ratio observed in the present study, however, is difficult to compare since we have excluded
49 285 revascularizations among patients with acute myocardial infarction which were considered in
50 286 other reports (6). Therefore, the PCI to CABG ratio in Spain might be even higher. This large
51 287 difference in our country may be due to several factors such as difficulties in accessing one of the
52 288 therapies, poor adherence to therapeutic recommendations, underindication of revascularization,
53 289 or the characteristics of coronary heart disease in the Spanish population being different from
54 290 those in other developed countries. Furthermore, we detected large and increasing differences
55 291 between men and women depending on the type of revascularization (see figure 2), which
56 292 probably denotes a limited access of women to the healthcare system.

57 293
58 294
59 295
60

1
2
3 293 A significant worsening of the risk profile has been observed for both PCI and CABG
4 294 patients: 14% raise in the prevalence of diabetes, 6-fold increase of patients with severe chronic
5 295 kidney disease or COPD by 2 (see Table 1). In general, the poorer risk profile of patients is
6 296 consistent with a progressive aging and a higher prevalence and severity of cardiovascular risk
7 297 factors observed in Spain and other countries(22- 24). Despite the conflicting evidence on the
8 298 benefit of off pump CABG or multiple arterial grafts revascularization, in Spain there has been
9 299 an increase in the number of patients operated on with two or more internal thoracic arterial grafts
10 300 (8% in the first period Vs. 23.6% between 2013 and 2017($p_{LT}<0.001$)) or off pump (31.3% Vs
11 301 34.2% in the first and last period respectively, $p_{LT}<0.001$)(25,26). Regarding PCI,
12 302 revascularizations with drug eluting stents grew as bare metal stents less became less frequently
13 303 used.

14 304 The increase in the proportion of patients requiring a new revascularization increased
15 305 throughout the study (see Table 1 and Supplementary material). This increase was more notable
16 306 in PCI and, above all, at the expense of a previous percutaneous revascularization. This finding
17 307 is consistent with the sustained increase in revascularizations over time, the lower need for re-
18 308 intervention after CABG, and the preference for percutaneous approaches in the global series
19 309 (1,2,6,8, 19, 20) (Table 1 and Supplementary Figure 5).

20 310 Mortality after CABG in Spain has decreased from 6.5% in 1998 to 2.6% in 2017 and is
21 311 now similar to that of other countries (22). The strong reduction of mortality is a common finding
22 312 too: for example, the registry for New South Wales detected a reduction of in hospital mortality
23 313 after CABG of 30% between 2000 and 2013(27). A significant 4- fold reduction in risk-adjusted
24 314 mortality was observed too between 1998 and 2017 (0.44) (1.55 to 0.44($p_{LT}<0.001$)).

25 315 Hospital mortality after PCI in Spain was similar to that of other developed
26 316 countries(28,29), and slightly grew throughout the series. When adjusting for patient
27 317 comorbidities and other confounding factors, the RAMR was reduced by almost 40% (1.42 to
28 318 1.05($p_{LT}<0.001$)).

29 319 We have detected a fourfold growth of the number of centers that perform PCI without
30 320 CABG (see Supplementary Table 6). Between 2013 and 2017, 41.1% of the patients treated with
31 321 PCI were revascularized in a center without coronary surgery. In addition, there has been a very
32 322 significant reduction in the median number of CABG procedures per center between the first and
33 323 last period of the study (130.5 Vs 75.5, $p_{LT}<0.001$). This volume of interventions per center is
34 324 different from that reported by Goicolea et al. (15) who detected a mean number of CABG
35 325 procedures of 95/year between 2013 and 2015. Goicolea et al. misclassified procedures such as
36 326 combined surgery of the aorta, pericardium, ventricular remodeling or cardiac arrhythmias as
37 327 isolated coronary surgery interventions, which can explain the differences. In any case, the
38 328 volume of CABG or PCI per center in Spain is very low. For example, in Europe, hospitals with
39 329 an intermediate volume of CABG perform between 125 and 450 procedures per year(30) and the
40 330 EACTS/ESC Myocardial Revascularization Guidelines recommend a minimum of 200 isolated
41 331 CABG interventions to maintain viable coronary surgery programs(1).

42 332 There is an important relationship between the volume of CABG per center and in-
43 333 hospital mortality, such that as the volume of the centers increases, mortality decreases. On the
44 334 contrary, mortality after PCI increases as the volume of interventions increases (Table 2 and
45 335 Supplementary Material). The latter can be explained by the fact that patients referred to centers
46 336 with greater activity may have anatomical characteristics or comorbidities that confer a greater
47 337 risk, and which have not been adequately contemplated in this study (i.e.: left man disease,
48 338 severely calcified coronary arteries, poor left ventricular function...).

339 340 *Conclusions*

341
342 From 1998 to 2017 there has been a significant increase in the volume of
343 343 revascularizations in Spain. This growth has been uneven, with more PCI and a gradual reduction
344 344 in CABG. Risk-adjusted mortality has been significantly reduced in both arms, although the
345 345 reduction has been particularly pronounced among surgically revascularized patients. Finally, in
346 346 Spain, there is not an adequate balance between the volume of revascularizations and the number

1
2
3 347 of hospitals, with centers with a low number of CABG procedures and a great proportion of
4 348 hospitals with PCI programs but without CABG onsite.

5 349
6 350 *Limitations*

7 351
8 352 These conclusions have to be taken with caution due to possible coding biases and others
9 353 inherent to administrative databases analyses. Beyond a real change, the variation in the
10 354 prevalence of comorbidities can be also partially explained by changes and errors in coding
11 355 throughout de study period. Surgical turndowns are known to have higher risk despite risk
12 356 adjustment, but they could not be identified in this dataset. We could not estimate operative or
13 357 cardiovascular risks according to validated clinical scores in cardiac surgery or cardiology (such
14 358 as EuroSCORE, Framingham Risk Score or NCDR CathPCI Mortality risk) given that the items
15 359 of these scores are not available in the MBDS. The MBDS does not contain information on private
16 360 activity in Spain.
17 361

18 362

19 363 **Footnotes:**

20 364 **Author Contributions:** MCA, DHV, HCG, LCMC, JLM, contributed to developing the design
21 365 of the study. MCA and LCMC requested the information from the Spanish Department of Health.
22 366 MCA, MP, JAM, CV, IP and GCC contributed to interpreting the data. MCA, JCC, DHV
23 367 performed the statistical analysis. AF and LCMC contributed to the critical review of the paper.
24 368 MCA is the guarantor of this work and assumes full responsibility for the conduct of the study

25 369 **Funding Statement:**

26 370 This research received no grant from any funding agency in the public, commercial or not-for-
27 371 profit sectors

28 372 **Competing interests:** None.

29 373 Patient consent for publication: Not required

30 374 **Ethics approval:** This study was approved by the Institutional Review Board and Ethics
31 375 Committee at Hospital Clínico San Carlos (Madrid)

32 376 **Data availability statement:** Extra data can be accessed via the Dryad data repository at
33 377 <http://datadryad.org/> with the doi:10.5061/dryad.gqnk98smk

1
2
3 379 **References:**
4 380

- 5 381 1. Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. 2018
6 382 ESC/EACTS Guidelines on myocardial revascularization. *Eur Heart J.*2019;40:87-165.
7 383 2. Mohr FW, Morice MC, Kappetein AP, Feldman TE, Ståhle E, Colombo A, et al. Coronary
8 384 artery bypass graft surgery versus percutaneous coronary intervention in patients with three-
9 385 vessel disease and left main coronary disease: 5-year follow-up of the randomized, clinical
10 386 SYNTAX trial. *Lancet.*2013;381:629–38.
11 387 3. Blumenfeld O, Na'amnih W, Shapira-Daniels A, Lotan C, Shohat T, Shapira OM. Trends in
12 388 Coronary Revascularization and Ischemic Heart Disease-Related Mortality in Israel. *J Am Heart*
13 389 *Assoc.*2017;6:e004734.
14 390 4. Epstein AJ, Polsky D, Yang F, Yang L, Groeneveld PW. Coronary revascularization trends in
15 391 the United States, 2001-2008. *JAMA.*2011;305:1769-76.
16 392 5. Ko W, Tranbaugh R, Marmur JD, Supino PG, Borer JS. Myocardial Revascularization in New
17 393 York State: Variations in the PCI-to-CABG Ratio and Their Implications. *J Am Heart*
18 394 *Assoc.*2012;1:e001446.
19 395 6. Health at a Glance: Europe 2016. State Of Health In The Eu Cycle. Available at:
20 396 https://ec.europa.eu/health/sites/health/files/state/docs/health_glance_2016_rep_en.pdf.
21 397 Accessed April 28,2020.
22 398 7. Cuerpo G, Carnero M, Hornero Sos F, Polo ML, Centella Hernandez T, Gascón P, et al. Cirugía
23 399 cardiovascular en España en el año 2018. Registro de intervenciones de la Sociedad Española de
24 400 Cirugía Torácica-Cardiovascular. *Cir Cardiovasc.*2019;26:248-64.
25 401 8. Cid Álvarez AB, Rodríguez Leor O, Moreno R, Pérez de Prado A. Registro Español de
26 402 Hemodinámica y Cardiología Intervencionista. XXVII Informe Oficial de la Sección de
27 403 Hemodinámica y Cardiología Intervencionista de la Sociedad Española de Cardiología (1990-
28 404 2017). *Rev Esp Cardiol.*2018;71:1036-46.9. Mack MJ, Herbert M, Prince S, Dewey TM, Magee
29 405 MJ, Edgerton JR. Does reporting of coronary artery bypass grafting from administrative databases
30 406 accurately reflect actual clinical outcomes?. *J Thorac Cardiovasc Surg.*2005;129:1309–17.
31 407 10. Íñiguez Romo A, Bertomeu Martínez V, Rodríguez Padial L, Anguita Sanchez M, Ruiz
32 408 Mateas F, Hidalgo Urbano R, et al. The RECALCAR Project. Healthcare in the Cardiology Units
33 409 of the Spanish National Health System, 2011 to 2014. *Rev Esp Cardiol (Engl Ed).*2017;70:567-
34 410 575.
35 411 11. Rodríguez-Padial L, Bertomeu V, Elola FJ, Anguita M, Fernandez Lozano I, Sila L, et al.
36 412 Quality improvement Strategy of the Spanish Society of Cardiology: The RECALCAR Registry.
37 413 *J Am Coll Cardiol.*2016;68:1140-2.
38 414 12. Bertomeu V, Cequier Á, Bernal JL, Alfonso F, Anguita M, Barrabés JA, et al. In-hospital
39 415 mortality due to acute myocardial infarction. relevance of type of hospital and care provided.
40 416 RECALCAR study. *Rev Esp Cardiol(Engl Ed).*2013; 66:935-42.
41 417 13. Gutacker N, Bloor K, Cookson R, Garcia-Armesto S, Bernal-Delgado E. Comparing hospital
42 418 performance within and across countries: an illustrative study of coronary artery bypass graft
43 419 surgery in England and Spain. *Eur J Public Health.*2015;25 Suppl 1:28–34.
44 420 14. Goicolea Ruigómez FJ, Elola FJ, Durante-López A, Fernández Pérez C, Bernal JL, Macaya
45 421 C. Coronary artery bypass grafting in Spain. Influence of procedural volume on outcomes. *Rev*
46 422 *Esp Cardiol (Engl Ed).*2020[Epub ahead of print].
47 423 15. INEbase [Internet]. Madrid: Instituto Nacional de Estadística (Spain); [cited 2019, July, 20].
48 424 Available from: <http://www.ine.es/>.
49 425 16. Charlson ME, Szatrowski TP, Peterson J, Gold J. Validation of combined comorbidity index.
50 426 *J Clinical Epidemiol.*1994;47:1245-51.
51 427 17. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, et al. Validation of the combined
52 428 comorbidity index of Charlson and Elixhauser to predict 30-day mortality across ICD 9 and ICD
53 429 10. *Med Care.*2018;56:812.
54 430 18. Epstein AJ, Polsky D, Yang F, Yang L, Groeneveld PW. Coronary Revascularization trends
55 431 in the United States:2001-2008. *JAMA.*2011;305:1769–1776.
56 432

- 1
2
3 433 19. Stephan Windecker, Philippe Kolh, Fernando Alfonso, Jean-Philippe Collet, Jochen Cremer,
4 434 Volkmar Falk, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task
5 435 Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the
6 436 European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special
7 437 contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI).
8 438 *Eur Heart J.* 2014;35:2541-619.
- 9 439 20. Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, et al. Strategies for
10 440 multivessel revascularization in patients with diabetes. *N Engl J Med.* 2012;367:2375-84.
- 11 441 21. Becker ER, Granzotti AM. Trends in In-hospital Coronary Artery Bypass Surgery Mortality
12 442 by Gender and Race/ Ethnicity –1998-2015: Why Do the Differences Remain?. *J Natl Med*
13 443 *Assoc.* 2019;111:527-539.
- 14 444 22. Cornwell LD, Omer S, Rosengart T, Holman WL, Bakaeen FG. Changes over time in risk
15 445 profiles of patients who undergo coronary artery bypass graft surgery: the Veterans Affairs
16 446 Surgical Quality Improvement Program (VASQIP). *JAMA Surg.* 2015;150:308-15
- 17 447 23. Beckmann A, Meyer R, Lewandowski J, Markewitz A, Harringer W. German Heart Surgery
18 448 Report 2018: The Annual Updated Registry of the German Society for Thoracic and
19 449 Cardiovascular Surgery. *Thorac Cardiovasc Surg.* 2019;67:331-344.
- 20 450 24. Vora AN, Dai D, Gurm H, Amin AP, Messenger JC, Mahmud E, et al. Temporal Trends in
21 451 the Risk Profile of Patients Undergoing Outpatient Percutaneous Coronary Intervention: A Report
22 452 from the National Cardiovascular Data Registry's CathPCI Registry. *Circ Cardiovasc*
23 453 *Interv.* 2016;9:e003070.
- 24 454 25. Taggart DP, Altman DG, Gray AM, Lees B, Nugara F, Yu LM, et al. Randomized trial to
25 455 compare bilateral vs. single internal mammary coronary artery bypass grafting: 1-year results of
26 456 the Arterial Revascularisation Trial (ART). *Eur Heart J.* 2010;31:2470-81.
- 27 457 26. Shroyer AL, Hattler B, Wagner TH, Collins JF, Baltz JH, Quin JA, et al. Five-Year Outcomes
28 458 after On-Pump and Off-Pump Coronary-Artery Bypass. *N Engl J Med.* 2017;377:623-632.
- 29 459 27. Brieger DB, Ng ACC, Chow V, D'Souza M, HyunK, Bannon PG, et al. Falling hospital and
30 460 postdischarge mortality following CABG in New South Wales from 2000 to 2013. *Open*
31 461 *Heart.* 2019;6:e000959.
- 32 462 28. Tran DT, Barake W, Galbraith D, Norris C, Knudtson ML, Kaul Pet al. Total and Cause-
33 463 Specific Mortality After Percutaneous Coronary Intervention: Observations From the Alberta
34 464 Provincial Project for Outcome Assessment in Coronary Heart Disease Registry. *CJC Open.*
35 465 2019;1:182-189.
- 36 466 29. Spoon DB, Psaltis PJ, Singh M, Holmes DR Jr, Gersh BJ, Rihal CS, et al. Trends in cause of
37 467 death after percutaneous coronary intervention. *Circulation.* 2014;129:1286-94.
- 38 468 30. Gutacker N, Bloor K, Cookson R, Gale CP, Maynard A, Pagano D, et al. Hospital Surgical
39 469 Volumes and Mortality after Coronary Artery Bypass Grafting: Using International
40 470 Comparisons to Determine a Safe Threshold. *Health Serv Res.* 2017;52:863-878.
- 41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

°	CABG					PCI					TOTAL		
	1998-2002	2003-2007	2008-2012	2013-2017	p _(TL)	1998-2002	2003-2007	2008-2012	2013-2017	p _(TL)	CABG	PCI	p
n(%) ^a	27141(31)	24521(16.7)	21584(11.7)	20436(11)	<0.001	60440(69)	122310(83.3)	162846(88.3)	164698(89)	<0.001	93682(15.5)	5102294(84.5)	<0.001
Age(years)	64.9±9.5	66±9.7	66.1±10	66.3±9.7	<0.001	64±11	65.9±11.1	67±11.5	67.6±11.6	<0.001	65.8±9.7	66.6±11.5	<0.001
Age(ranges)					<0.001*					<0.001*			
≤60	7634(28.1)	6498(26.5)	5797(26.8)	5360(26.2)	<0.001	20883(34.6)	36802(30.1)	45210(27.8)	44779(27.2)	<0.001	25285(27)	147674(28.9)	<0.001
60-70	10292(37.9)	8073(32.9)	7209(33.4)	7230(35.4)	<0.001	19442(32.2)	34783(28.4)	451752(27.7)	45878(27.9)	<0.001	32805(35)	145275(28.5)	<0.001
70-80	8684(32)	9077(37)	7436(34.4)	6579(32.2)	<0.001	17406(28.8)	40393(33)	51357(31.5)	46378(28.8)	<0.001	31776(33.9)	156540(30.7)	<0.001
>80	531(2)	873(3.6)	1147(5.3)	1267(6.2)	<0.001	2711(4.5)	10338(8.5)	21096(13)	26647(16.2)	<0.001	3818(4.1)	60794(11.9)	<0.001
Female sex	5379(19.8)	4768(19.5)	3776(17.5)	3353(16.4)	<0.001	13191(21.8)	29700(24.3)	39773(24.4)	39387(23.9)	<0.001	17276(18.4)	122046(23.9)	<0.001
High blood pressure	12264(45.2)	14540(59.3)	14166(65.6)	13896(68)	<0.001	26005(43)	68897(56.3)	100802(61.8)	103762(63.1)	<0.001	54866(58.6)	299466(58.7)	0.05
Previous MI ^b	3471(12.8)	3944(16.1)	3328 (15.4)	4132 (20.2)	<0.001	11383(18.8)	29608(24.2)	4669 (28.7)	58465(35.5)	<0.001	14875 (15.9)	146150(28.6)	<0.001
NSTEACS	8189(30.2)	6085(24.8)	4538(21)	4236(20.7)	<0.001	25495(42.2)	44821(36.6)	53322(32.7)	54260(33)	<0.001	23048(24.6)	177898(34.9)	<0.001
CHF ^b	1498(5.5)	1737(7.1)	2101(9.7)	2111(10.3)	<0.001	2745(4.5)	9475(7.8)	17662(10.9)	21218(12.9)	<0.001	7447(8)	51100(10)	<0.001
PVD ^b	1750(6.5)	2240(9.1)	2238(10.4)	2182(10.7)	<0.001	4431(7.3)	10380(8.5)	12581(7.7)	12754(7.7)	<0.001	8410(9)	40146(7.7)	<0.001
CVD^b	745(2.7)	1122(4.6)	1221(5.7)	1361(6.7)	<0.001	897(1.5)	2566(2.1)	4410(2.7)	4911(3)	<0.001	4449(4.8)	12784(2.5)	<0.001
Diabetes ^b	7493(27.6)	8799(35.9)	8509(39.4)	8804 (43.1)	<0.001	13131(21.7)	37880(31)	55245(33.9)	57511(34.9)	<0.001	33605(35.9)	163767(32.1)	<0.001
CKD ^b	423(1.6)	701(2.9)	1441(6.7)	1952(9.6)	<0.001	1066(1.8)	3689(3)	12165(7.5)	16094(9.8)	<0.001	4517(4.8)	33014(6.5)	<0.001
COPD ^b	959(3.5)	1396(5.7)	1322(6.1)	1518(7.4)	<0.001	2241(3.7)	6276(5.1)	10268(6.3)	12677(7.7)	<0.001	5195(5.6)	31462(6.2)	<0.001
Liver failure ^b	241(0.9)	331(1.4)	410(1.9)	560(2.7)	<0.001	460(0.8)	1392(1.1)	2497(1.5)	3496(2.2)	<0.001	1541(1.6)	8046(1.6)	0.11
Charlson's Index	2.7(1.4)	3.1(1.5)	3.3(1.7)	3.5(1.8)	<0.001	2.6(1.5)	3(1.7)	3.4(1.9)	3.6(2)	<0.001	3.1(1.6)	3.3(1.9)	<0.001
Previous CABG	1101(4.1)	1085(4.4)	146(0.7)	146(0.7)	<0.001	1727(2.9)	3374(2.8)	4359(2.7)	5417(3.3)	<0.001	2475(2.6)	14877(2.9)	<0.001
Previous PCI	1573(5.8)	1990(8.1)	2704(12.5)	3204(15.7)	<0.001	8163(13.5)	23004(18.8)	40898(25.1)	47890(29.1)	<0.001	9470(10.1)	119955(23.5)	<0.001
Hospital without CABG on site						10151(17.4)	36425(30.7)	64882 (40.9)	65260(40.9)	<0.001		173718(35.7)	
Revascularization 3+ vessels	11326 (41.7)	9206(37.5)	7947(36.8)	7357(36)	<0.001	-	-	11312(7)	11792(7.2)	<0.001	32849(40.5)	23106/327528 (7.1)	<0.001
Outpatient PCI						-	1371(1.1)	7200(4.4)	6358(3.9)	<0.001		14933/449843 (3.3)	
BMS						60107(99.5)	91516(74.8)	67018 (41.2)	34090 (20.7)	<0.001		252731(49.5)	
DES							34873(28.5)	89198(54.8)	115643(70.2)	<0.001		239714/449843(53.3)	
IVUS							1037(0.9)	6104(3.8)	4517(2.7)	<0.001		11658/449843 (2.6)	
ITA	19643(72.3)	21635(88.2)	19646(90.9)	19928(96.9)	<0.001	-	-	-	-	-	80852(86.1)	-	-
Bilateral ITA	2168(8)	3218(13.1)	3454(16)	4816(23.6)	<0.001	-	-	-	-	-	13654(14.6)	-	-
Off Pump CABG	8496(31.3)	8708(35.5)	7178(33.3)	6984(34.2)	<0.001	-	-	-	-	-	31365(33.5)	-	-
Hospital Volume					<0.001*					<0.001*			<0.001
Low	3868(15.1)	3053(12.6)	2404(11.2)	2080(10.2)	<0.001	3259(5.6)	6004(5.1)	7612(4.8)	8002(5)	<0.001	11405(12.4)	24877(5)	<0.001
Low- Interm	5511(21.5)	4671(19.3)	4272(19.9)	3901(19.1)	<0.001	8150(14)	17226(14.5)	21447(13.5)	23155(14.2)	<0.001	18255(20)	69988(14.1)	<0.001
Interm- High	7149(27.8)	6984(28.8)	6446(30)	5693(27.9)	<0.001	15949(27.4)	33545(28.3)	45083(28.5)	47527 (29.7)	<0.001	26272(28.6)	142104(28.7)	0.128
High	9156(35.7)	9524(39.3)	8377(39)	8708(42.7)	<0.001	30870(53)	61902(52.2)	84335(53.2)	80730(51)	<0.001	35765(40)	257837(52.1)	<0.001

Table 1. Baseline and procedural characteristics of PCI (percutaneous coronary intervention) or CABG (Coronary artery bypass grafting). Data is expressed with n(%) or mean SD. p_(TL) contrast test for linear trend. *No contrast for linear trend. a. Number of CABG or PCI divided by the volume of revascularizations. b. according to Charlson's index definition(16,17). MI: Myocardial infarction. CHF: Congestive heart failure. PVD: peripheral vascular disease. CKD: Chronic kidney disease. CVD: Cerebrovascular disease. COPD: Chronic obstructive pulmonary disease. BMS: bare metal stent, DES: drug eluting stent ITA: internal thoracic artery.

CABG			PCI		
Variable	OR CI 95%	p	Variable	OR CI 95%	p
Region of Spain	Not Shown	<0.001	Region of Spain	Not Shown	<0.001
Hospital Volume of CABG (as compared to Low Volume centres)			Hospital Volume of PCI (as compared to Low Volume centres)		
Low-Intermediate	0.86(0.77;0.95)	0.004	Low-Intermediate	1.4(1.18;1.68)	<0.001
Intermediate-High	0.81(0.73;0.9)	<0.001	Intermediate-High	2.05(1.67;2.36)	<0.001
High	0.77(0.68;0.86)	<0.001	High	2.05(1.73;2.42)	<0.001
COPD	1.35(1.2;1.53)	<0.001	COPD	1.25(1.15;1.35)	<0.001
Age (as compared to <60)			Age (as compared to <60)		
60-70	1.72(1.55;1.91)	<0.001	60-70	1.69(1.54;1.85)	<0.001
70-80	3.02(2.73;3.33)	<0.001	70-80	2.6(3.38;2.84)	<0.001
>80	5.07(4.38;5.88)	<0.001	>80	3.58(3.26;3.93)	<0.001
Female sex	1.14(1.06;1.23)	0.001	Female sex	1.09(1.03;1.15)	0.004
Previous MI	2.81(2.62;3.01)	<0.001	Previous MI	2.62(2.49;2.76)	<0.001
NSTE ACS as primary diagnosis	1.2(1.12;1.28)	<0.001			
CHF	3.21(2.96;3.49)	<.001	CHF	4.63(4.39;4.9)	<0.001
PVD	1.43(1.29;1.57)	<.001	PVD	1.24(1.15;1.34)	<0.001
CVD	1.72(1.52;1.94)	<.001	CVD	2.29(2.08;2.52)	<0.001
CKD	1.75(1.55;1.99)	<.001	CKD	1.56(1.45;1.67)	<0.001
On pump CABG	1.09(1.02;1.17)	0.017			
Bilateral ITA	0.8 (0.71; 0.89)	0.042			
Period of study (as compared to 1997-2002)			Period of study (as compared to 1997-2002)		
2003-2007	0.66(0.61;0.72)	<0.001	2003-2007	1.09(0.99;1.21)	0.09
2008-2012	0.41(0.38;0.46)	<0.001	2008-2012	1.18(1.06;1.31)	0.002
2013-2017	0.29(0.26;0.32)	<0.001	2013-2017	1.18(1.06;1.32)	0.002
			Hospital without CABG on site	0.86(0.8;0.92)	<.001
			Diabetes	1.58(1.45;1.67)	<.001
			BMS	0.86(0.79;0.94)	<0.001
			DES	0.41(0.38;0.45)	0.001

Table 2. Factors associated to in-hospital mortality. CABG: coronary artery bypass grafting. PCI: percutaneous coronary intervention. COPD: chronic obstructive pulmonary disease. MI: myocardial infarction. NSTEMI: non-ST elevation acute coronary syndrome. PVD: peripheral vascular disease. CHF: congestive heart failure. CVD: cerebrovascular disease. CKD: chronic kidney disease. ITA: Internal thoracic artery. BMS: Bare meta stent. DES: Drug eluting stent.

1
2
3 Figure 1. Flow diagram. Selection of episodes.
4

5
6 Figure 2. Number of procedures per million inhabitants and year. A) Volume of procedures per
7 year. Number of total revascularizations and CABG are shown. B) number of procedures by sex
8 and million inhabitants. The number of procedures of each type is represented by sex and million
9 inhabitants of each sex throughout the study period.

10
11 Figure 3. Number of procedures per million inhabitants and year in age ranges. A: PCI B: CABG
12

13
14 Figure 4. Non adjusted and adjusted in-hospital mortality. RAMR: Risk adjusted mortality rate.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Flow diagram. Selection of episodes.

83x134mm (300 x 300 DPI)




Figure 2. Number of procedures per million inhabitants and year. A) Volume of procedures per year. Number of total revascularizations and CABG are shown. B) number of procedures by sex and million inhabitants. The number of procedures of each type is represented by sex and million inhabitants of each sex throughout the study period.

83x116mm (300 x 300 DPI)




Figure 3. Number of procedures per million inhabitants and year in age ranges. A: PCI B: CABG

83x110mm (300 x 300 DPI)




Figure 4. Non adjusted and adjusted in-hospital mortality. RAMR: Risk adjusted mortality rate.

83x111mm (300 x 300 DPI)

Supplementary Material

Table 1. ICD9 and ICD10 codes

	ICD9	ICD10
CABG	36.1x	0210xxx,0211xxx,0212xxx,0213xxx
PCI	00.66, 36.03, 36.06, 36.07, 36.09	0270xxx, 0271xxx,0272xxx,0273xxx, 02C0xxx, 02C1xxx, 02C2xxx, 02C3xxx, 02C4xxx
Excluded Concomitant procedures	35.xx, 37.3x, 37.51, 38.44, 38.45, 39.1x, 39.2x, 39.3x & 37.90	027Fxxx, 027Gxxx, 02NFxxx, 02NGxxx, 02Vxxxx, 027Jxxx, 02NJxxx, 02Nxxxx, 02Rxxxx, 02Qxxxx, 028xxxx, 02Bxxxx, 02Cxxxx (different from 02C0xxx, 02C1xxx, 02C3xxx and 02C4xxx), 02Fxxxx, 02Hxxxx, 02Jxxxx, 02Kxxxx, 02Nxxxx, 02Pxxxx, 02Uxxxx, 02Wxxxx, 02Yxxxx, 025xxxx
STEMI	410.x1	I21.x9, I21.x1, I21.x, I21.4, I21.3, I21.9

CABG: coronary artery bypass grafting. PCI: percutaneous coronary intervention. AMI: acute myocardial infarction STEMI: ST elevation myocardial infarction

Table 2. Excluded volume and main reasons for exclusion throughout the study period.

	1997-2002	2003-2007	2008-2012	2013-2017	Total	p _{LT}
N	123593	229843	304095	320266	977797	
Acute STEMI	24316 (19.7)	60527 (26.3)	89136 (29.3)	99969 (31.2)	273948 (28)	<0.001
Coding *	7048 (5.7)	16264 (7.1)	28490 (9.4)	36700 (11.5)	88502 (9.1)	<0.001
Concomitant procedures	6319 (5.1)	11559 (5)	12603 (4.1)	15173 (4.7)	45654 (4.7)	<0.001
PCI & CABG in the same episode	447 (0.4)	580 (0.3)	777 (0.3)	781 (0.2)	2585 (0.3)	<0.001
Age <18 or >100	179 (0.1)	193 (0.1)	236 (0.1)	175 (0.1)	783 (0.1)	<0.001
Exclusion	36012 (29.1)	83012 (36.1)	119665 (39.4)	135132 (42.2)	373821 (38.2)	<0.001

PCI: Percutaneous coronary intervention. CABG: Coronary artery bypass grafting. LT: Linear trend. * Including coding errors, consolidated episodes, staged procedures..

Figure 1. Changes in the volume of excluded episodes.




Figure 2. Absolute number of procedures per year.





Figure 3. Absolute number of procedures depending on coronary syndrome.



It is observed that the proportion of CABG performed in patients with NSTEMI remained stable throughout the study period. However, there was a more marked increase in the number of PCI procedures in patients without NSTEMI. NSTEMI: non-ST elevation acute coronary syndrome.

Figure 4. Mean modified Charlson's Index.





Figure 5. Previous revascularization



Proportion of CABG or PCI patients with previous coronary surgery or percutaneous coronary intervention. The proportion of CABG with previous CABG significantly decreased (4.1% Vs 0.7%, $p_{LT} < 0.001$). Proportion of PCI with previous CABG increased from 2.9% to 3.3% ($p_{LT} < 0.001$). Proportion of CABG patients with previous PCI increased from 5.8% to 15.7% ($p_{LT} < 0.001$). Proportion of PCI patients with previous PCI increased from 13.5% to 29.1% ($p_{LT} < 0.001$).

	CABG					PCI					TOTAL		
	1998-2002	2003-2007	2008-2012	2013-2017	p _(TL)	1998-2002	2003-2007	2008-2012	2013-2017	p _(TL)	CABG	PCI	p
n(%) ^a	7494 (36.3)	8799 (18.9)	8509 (13.4)	8805 (13.3)	<0.001	13131 (63.7)	37878 (81.2)	55246 (86.7)	57518 (86.7)	<0.001	33607 (17)	163773 (83)	<0.001
Revascularization 3+ vessels	2118(32.7)	2182(28.4)	2043(27.4)	1835(22.9)	<0.001	-	-	4853 (8.9)	4876 (8.5)	<0.001	8178 (27.6)	9729/112764 (8.6)	<0.001
Number of stents													
<3								44791 (81.1)	51306 (91.2)	<0.001		96097/112764 (85.2)	<0.001
≥3								10455 (18.9)	6212 (10.8)	<0.001		16667/112764(14.8)	<0.001
BMS						60440 (99.5)	91514 (74.8)	67011 (41.2)	34085 (20.7)	<0.001		252715(20.7)	<0.001
DES							34868 (28.5)	89196 (54.8)	115652 (70.2)	<0.001		239716 (47)	<0.001
Bilateral ITA	519 (6.9)	1037 (11.8)	1175 (13.8)	1844 (20.9)	<0.001	-	-	-	-	-	4575 (13.6)	-	-
Off Pump CABG	8496(31.3)	8708(35.5)	7178(33.3)	6984(34.2)	<0.001	-	-	-	-	-	31365(33.5)	-	-

Table 3. Procedural characteristics of PCI (percutaneous coronary intervention) or CABG (Coronary artery bypass grafting) among patients with diabetes. Data is expressed with n(%). p_(TL) contrast test for linear trend. *No contrast for linear trend. a. Number of CABG or PCI divided by the volume of revascularizations in diabetic patients. BMS: bare metal stent, DES: drug eluting stent ITA: internal thoracic artery.

Table 4. Variables included in the model to detect factor associated to in-hospital mortality after CABG and PCI.

	Model to detect factors associated for in hospital mortality after CABG	Model to detect factors associated for in hospital mortality after PCI
Variables	Spanish region, Groups of hospitals according to the volume of CABG/year-center, COPD, Age ranges, Sex, Previous MI, NSTEMI on admission, PVD, CVD, Diabetes, CKD, Previous CABG, Previous PCI, Off-Pump, CHF, bilateral ITA, Period of study	CABG on site, Spanish region, Groups of hospitals according to the volume of PCI/year-center, COPD, Age ranges, Sex, Previous MI, NSTEMI on admission, PVD, CVD, Diabetes, CKD, Previous CABG, Previous PCI, BMS, DES, CHF, Period of study
AUC	0.76 (95%CI 0.76;0.77)	0.81 (95%CI 0.81;0.82)


CABG: coronary artery bypass grafting. PCI: percutaneous coronary intervention. COPD: chronic obstructive pulmonary disease. MI: myocardial infarction. NSTEMI: non-ST elevation acute coronary syndrome. PVD: peripheral vascular disease. CHF: congestive heart failure. CVD: cerebrovascular disease. CKD: chronic kidney disease. ITA: Internal thoracic artery. BMS: implantation of bare metal stent. DES: Implantation of drug eluting stent. AUC Area Under the Curve.

Table 5. Variables included in the model to estimate expected in-hospital mortality after CABG and PCI.

	Model to detect factors associated for in hospital mortality after CABG	Model to detect factors associated for in hospital mortality after PCI
Variables	Spanish region, Groups of hospitals according to the volume of CABG/year-center, COPD, Age ranges, Sex, Previous MI, NSTEMI on admission, PVD, CVD, Diabetes, CKD, Previous CABG, Previous PCI, Off-Pump, CHF, bilateral ITA, High blood pressure	CABG on site, Spanish region, Groups of hospitals according to the volume of PCI/year-center, COPD, Age ranges, Sex, Previous MI, NSTEMI on admission, PVD, CVD, Diabetes, CKD, Previous CABG, Previous PCI, BMS, DES, CHF, high blood pressure.
AUC	0.74 (95%CI 0.73;0.75)	0.81 (95%CI 0.81;0.82)

CABG: coronary artery bypass grafting. PCI: percutaneous coronary intervention. COPD: chronic obstructive pulmonary disease. MI: myocardial infarction. NSTEMI: non-ST elevation acute coronary syndrome. PVD: peripheral vascular disease. CHF: congestive heart failure. CVD: cerebrovascular disease. CKD: chronic kidney disease. ITA: Internal thoracic artery. BMS: implantation of bare metal stent. DES: Implantation of drug eluting stent. AUC Area Under the Curve.

Figure 6. Median Number of Procedures/Hospital- year and Number of Hospitals reporting data to MBDS.



Left axis: median procedures/hospital. Right axis: number of hospitals reporting data to MBDS

Table 6. Number of hospitals and volume of procedures/hospital in each study period

	1998-2002	2003-2007	2008-2012	2013-2017	p(LT)
Median number of hospitals/year					
(+)CABG(+)PCI	37(36;40)	44(42;44)	47(47;47)	48(45;50)	<0.001
(-)CABG(+)PCI	25(19;32)	61(54;62)	93(88;95)	96(77;99)	<0.001
Median number of procedures/center-year					
CABG	130.5(102;163)	103(73;145)	89(58;120)	75.5(50.5;114)	<0.001
PCI	148(58;249)	195(77;334)	186(71;340)	198(80.5;350.5)	<0.001
Mortality according to hospital volume of procedures					
Hospital Volume of CABG					
Low Volume	330/3866(8.5)	206/3053(6.8)	87/2406(3.6)	74/2079(3.6)	<0.001
Low-Intermediate	411/5511(7.5)	322/4671(6.9)	170/4272(4)	108/3901(2.8)	<0.001
Low-High	530/7149(7.4)	345/6984(4.9)	226/6446(3.5)	172/5694(3)	<0.001
High	469/9156(5.1)	352/9524(3.7)	265/8376(3.2)	222/8708(2.6)	<0.001
Hospital Volume of PCI					
Low Volume	18/3259(0.6)	31/6004(0.5)	45/7613(0.6)	65/8052(0.8)	0.04
Low-Intermediate	67/8160(0.8)	155/17226(0.9)	204/21446(1)	264/23081(1.1)	0.003
Low-High	172/15950(1.1)	426/33545(1.3)	682/45088(1.5)	758/47881(1.6)	<0.001
High	296/30869(1)	745/61896(1.2)	1225/84334(1.5)	1140/80415(1.4)	<0.001

Table 3. Data are shown as n(%) or median and IQR. CABG: "Coronary Artery Bypass Grafting". PCI: "Percutaneous Coronary Intervention. (+)CABG(+)PCI: Hospitals with CABG and PCI: (-)CABG(+)PCI. Hospitals without CABG but with PCI.

The RECORD statement – checklist of items, extended from the STROBE statement, that should be reported in observational studies using routinely collected health data.

	Item No.	STROBE items	Location in manuscript where items are reported	RECORD items	Location in manuscript where items are reported
Title and abstract					
	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found	Title	<p>RECORD 1.1: The type of data used should be specified in the title or abstract. When possible, the name of the databases used should be included.</p> <p>RECORD 1.2: If applicable, the geographic region and timeframe within which the study took place should be reported in the title or abstract.</p> <p>RECORD 1.3: If linkage between databases was conducted for the study, this should be clearly stated in the title or abstract.</p>	<p>Article Summary</p> <p>Title Article Summary</p> <p>NA</p>
Introduction					
Background rationale	2	Explain the scientific background and rationale for the investigation being reported	Introduction		
Objectives	3	State specific objectives, including any prespecified hypotheses	Introduction		
Methods					
Study Design	4	Present key elements of study design early in the paper	Article Summary		
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Materials and Methods		

Participants	6	<p>(a) <i>Cohort study</i> - Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up</p> <p><i>Case-control study</i> - Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls</p> <p><i>Cross-sectional study</i> - Give the eligibility criteria, and the sources and methods of selection of participants</p> <p>(b) <i>Cohort study</i> - For matched studies, give matching criteria and number of exposed and unexposed</p> <p><i>Case-control study</i> - For matched studies, give matching criteria and the number of controls per case</p>	Materials and Methods	<p>RECORD 6.1: The methods of study population selection (such as codes or algorithms used to identify subjects) should be listed in detail. If this is not possible, an explanation should be provided.</p> <p>RECORD 6.2: Any validation studies of the codes or algorithms used to select the population should be referenced. If validation was conducted for this study and not published elsewhere, detailed methods and results should be provided.</p> <p>RECORD 6.3: If the study involved linkage of databases, consider use of a flow diagram or other graphical display to demonstrate the data linkage process, including the number of individuals with linked data at each stage.</p>	<p>Materials and Methods and Supplemental material</p> <p>NA</p> <p>NA</p>
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable.	Materials and Methods and Supplemental Material	RECORD 7.1: A complete list of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be provided. If these cannot be reported, an explanation should be provided.	Materials and Methods and supplemental material
Data sources/ measurement	8	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Materials and Methods and Supplemental Material		

Bias	9	Describe any efforts to address potential sources of bias	Materials and Methods (Statistical Analysis)		
Study size	10	Explain how the study size was arrived at	Materials and Methods & Figure 1		
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen, and why	Materials and Methods		
Statistical methods	12	<p>(a) Describe all statistical methods, including those used to control for confounding</p> <p>(b) Describe any methods used to examine subgroups and interactions</p> <p>(c) Explain how missing data were addressed</p> <p>(d) <i>Cohort study</i> - If applicable, explain how loss to follow-up was addressed</p> <p><i>Case-control study</i> - If applicable, explain how matching of cases and controls was addressed</p> <p><i>Cross-sectional study</i> - If applicable, describe analytical methods taking account of sampling strategy</p> <p>(e) Describe any sensitivity analyses</p>	Materials and Methods (Statistical Analysis)		
Data access and cleaning methods		..	Materials and Methods	RECORD 12.1: Authors should describe the extent to which the investigators had access to the database population used to create the study population.	Materials and Methods and Introduction

				RECORD 12.2: Authors should provide information on the data cleaning methods used in the study.	Materials and Methods. Figure 1.
Linkage		..	NA	RECORD 12.3: State whether the study included person-level, institutional-level, or other data linkage across two or more databases. The methods of linkage and methods of linkage quality evaluation should be provided.	
Results					
Participants	13	(a) Report the numbers of individuals at each stage of the study (<i>e.g.</i> , numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed) (b) Give reasons for non-participation at each stage. (c) Consider use of a flow diagram	Results. Section: 2 <i>Study Population</i> “. Figure 1.	RECORD 13.1: Describe in detail the selection of the persons included in the study (<i>i.e.</i> , study population selection) including filtering based on data quality, data availability and linkage. The selection of included persons can be described in the text and/or by means of the study flow diagram.	Results. Section: 2 <i>Study Population</i> “. Figure 1.
Descriptive data	14	(a) Give characteristics of study participants (<i>e.g.</i> , demographic, clinical, social) and information on exposures and potential confounders (b) Indicate the number of participants with missing data for each variable of interest (c) <i>Cohort study</i> - summarise follow-up time (<i>e.g.</i> , average and total amount)	Results. Section: “ <i>Study Population</i> ” Table 1. Supplemental material.		
Outcome data	15	<i>Cohort study</i> - Report numbers of outcome events or summary measures over time <i>Case-control study</i> - Report numbers in each exposure	Results. Section “Mortality”		

		category, or summary measures of exposure <i>Cross-sectional study</i> - Report numbers of outcome events or summary measures			
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Results. Table 2. Section: “Mortality”		
Other analyses	17	Report other analyses done— e.g., analyses of subgroups and interactions, and sensitivity analyses	NA		
Discussion					
Key results	18	Summarise key results with reference to study objectives	Discussion. Par 1.		
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Discussion. Par 1 “Limitations” section	RECORD 19.1: Discuss the implications of using data that were not created or collected to answer the specific research question(s). Include discussion of misclassification bias, unmeasured confounding, missing data, and changing eligibility over time, as they pertain to the study being reported.	Discussion. Par 1 “Limitations” section
Interpretation	20	Give a cautious overall interpretation of results considering objectives,	Discussion. Par 1 “Conclusion” section		

		limitations, multiplicity of analyses, results from similar studies, and other relevant evidence			
Generalisability	21	Discuss the generalisability (external validity) of the study results	NA		
Other Information					
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Footnotes		
Accessibility of protocol, raw data, and programming code		..	Footnotes	RECORD 22.1: Authors should provide information on how to access any supplemental information such as the study protocol, raw data, or programming code.	Footnotes

*Reference: Benchimol EI, Smeeth L, Guttman A, Harron K, Moher D, Petersen I, Sørensen HT, von Elm E, Langan SM, the RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. *PLoS Medicine* 2015; in press.

*Checklist is protected under Creative Commons Attribution ([CC BY](https://creativecommons.org/licenses/by/4.0/)) license.